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Abstract 
Quasar S. Padiath, MBBS, PhD 
 
The Role of Lamin B1 in the Organization of the Nuclear Envelope and Myelin Regulation 
in Development and Disease 
 
Bruce Nmezi, PhD 
 
University of Pittsburgh, 2019 
 
 
Abstract 
The nuclear lamina is a structural meshwork composed of intermediate filament proteins 
known as lamins that maintains nuclear shape and function. Perturbations of lamins lead to 
diseases, collectively known as laminopathies, which affect a wide variety of organ systems. One 
such laminopathy is autosomal dominant leukodystrophy (ADLD), a severe and fatal adult-onset 
demyelinating laminopathy caused by overexpression of lamin B1, one of the lamin proteins that 
make up the nuclear lamina.  My studies aim to elucidate the role of lamin B1 in the organization 
of the nuclear envelope, its role in myelin regulation during oligodendrocyte maturation, and to 
understand how the genomic rearrangements involving LMNB1 cause ADLD. Our results suggest 
a novel concentric organization model of the nuclear lamina, with lamin B1 facing the inner 
nuclear membrane while lamins A and C together face the nucleoplasm. Lamin B1’s outward-
facing localization maintains nuclear shape by restraining the lamin A/C meshwork from 
protruding outward. To study lamin B1’s function in mature oligodendrocytes, conditional Lmnb1 
knockout mice were used to study behavioral and molecular changes in the central nervous system. 
Knockout mice did not exhibit any overt behavioral phenotypes or myelination defects, but a 
careful analysis revealed alterations in the number of myelinating oligodendrocyte populations. 
We conclude that while mature oligodendrocytes do not require lamin B1 for their proper function, 
it might be important for the regulation of oligodendrocyte cell number. Array CGH studies 
 v 
revealed that deletions upstream of LMNB1 can also lead to ADLD, while large duplications 
involving LMNB1 and a significant upstream region do not. Real-time PCR analysis demonstrate 
much higher LMNB1 expression in white matter than in grey matter and fibroblasts. We propose 
that an oligodendrocyte-specific silencer element lies upstream of LMNB1, explaining ADLD’s 
central nervous system exclusivity despite a constitutional LMNB1 duplication. As demyelination 
and white matter injuries are common in disorders affecting a wide age range – from preterm 
neonates to young adults and the elderly – researching pathways involved in myelination and ways 
to reverse it could have a significant impact to public health. 
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1.0 Introduction 
1.1 The Nuclear Lamina 
1.1.1  The structure of the nuclear lamina  
The nuclear lamina is a filamentous meshwork that lies beneath the inner nuclear 
membrane in all metazoan cells. It regulates the size, shape, and structural integrity of the nucleus 
(1). Type V intermediate filaments known as lamins constitute the nuclear lamina, of which two 
main types have been identified: A-type and B-type lamins. A-type lamins consist of lamins A and 
C, both of which are products of the LMNA gene in 1q21 through alternative splicing. B-type 
lamins consist of lamins B1 and B2, coded for by two different genes: LMNB1 in 5q23 and LMNB2 
in 19q23, respectively (2). Structurally, lamins have much in common with other intermediate 
filaments: they are composed of α-helical central rods flanked by an N-terminal globular “head” 
and a C-terminal “tail” domain (3). The central rod domains dimerize in a coiled-coil fashion, in 
turn assembling in a head-to-tail manner and associating laterally in a half-staggered, anti-parallel 
fashion to form filamentous arrays (Figure 1.1) (4, 5).  The nuclear lamina meshwork lies just 
beneath the inner nuclear membrane and can alter gene expression through chromatin interactions 
as well as affect the spacing of nuclear pore complexes (Figure 1.2) (6, 7). 
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Figure 1.1: Polymerization of lamin protein.
Lamin polypeptides dimerize at their central rod domains, which in turn associate in a head-to-tail manner. Polymers 
then associate laterally, in a half-staggered, antiparallel fashion to form filamentous arrays. 
Figure 1.2: Location of the nuclear lamina. 
The nuclear lamina is a meshwork of intermediate filaments within the nucleus, located underneath the inner nuclear 
membrane. It plays a role in chromatin organization. 
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1.1.2  Lamins in development 
A-type lamins are primarily expressed in differentiated cells, with some notable absences 
in certain tissues. For example, while neurons and glia within the central nervous system (CNS) 
are high in lamin C expression, they contain little to no lamin A. Lmna-null mice develop normally 
for the first few weeks, however, they succumb to muscular dystrophy and cardiomyopathy after 
4-6 weeks of age (8). In contrast, B-type lamins are expressed in all mammalian cells throughout 
development and differentiation, and Lmnb1-null mice die shortly after birth with skeletal and lung 
defects (9). Lmnb1-null studies must consequently be done in a tissue-specific or conditional 
knockout manner. Lmnb1 is required for proper mouse organogenesis as well as neuronal 
migration during development (10, 11), but the absence of Lmnb1 in mouse keratinocytes has  no 
effect on the proliferation or development of skin and hair cells (12). In these tissues, A-type lamins 
are hypothesized to be sufficient for maintaining skin cell proliferation and vitality in vivo. These 
data together show that lamin B1 can be of variable importance in different tissue types during 
development. Previously, it has been hypothesized that A-type and B-type lamins may be able to 
operate as independent network systems within the nucleus, as opposed to simply being 
incorporated into one large, heteromultimeric meshwork along the inner nuclear membrane (13-
15). Research on their spatial organization within the nuclear envelope was unclear until now: my 
dissertation will describe the various microscopic and biochemical methods utilized to elucidate 
nuclear lamina structure. 
In vitro studies show that A-type and B-type lamins operate independently to regulate 
nuclear shape and gene expression. Lmna-knockout studies in mouse embryonic fibroblasts 
demonstrate abnormally elongated nuclei with the loss of nuclear envelope proteins including B-
type lamins from one pole, through which herniations of chromatin may be seen (8). In contrast, 
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knockouts of Lmnb1 result in excessive nuclear envelope protrusions known as blebs, which 
almost exclusively contain A-type lamins, and are highly associated with gene-rich euchromatin 
(13). Depletion of either lamin A or lamin B1 results in abnormal chromatin decondensation and 
loss of heterochromatin (16, 17), suggesting that A-type and B-type lamins play supportive roles 
in chromatin organization.  
1.1.3  Post-translational processing of nuclear lamins 
B-type lamins and prelamin A (the precursor to mature lamin A protein), have a C-terminal 
CAAX motif (C = cysteine, A = aliphatic, X = any amino acid), to which farnesyltransferase 
enzymes add a 15-carbon farnesyl group onto the cysteine residue. This in turn leads to 
endoproteolytic release of the last 3 amino acids, and finally carboxymethlation of the remaining 
farnesylcysteine residue (18, 19). Prelamin A is processed into mature lamin A by 
metallopeptidase ZMPSTE24, which catalyzes proteolytic cleavage of 15 amino acids at the C-
terminus, losing the farnesyl moiety in the process (20-22). The C-terminal domains of B-type 
lamins are kept intact, remaining permanently farnesylated (Figure 1.3) (23). Lamin C, the shorter 
product of the LMNA gene through alternative splicing, is never farnesylated (24).  
It is hypothesized that this farnesyl group allows the B-type lamins to form a tight anchor 
within the inner nuclear membrane, affecting its localization within the nucleoskeleton. Inhibition 
of B-type lamin farnesylation through farnesyltransferase inhibitors or a mutation in the CAAX 
domain leads to its aberrant localization, malformed nuclei, and chromatin migration deficiencies 
in neurons (23, 25, 26). 
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Figure 1.3: Processing of lamins A/C and B1 (simplified). 
Lamin B1 precursor (green, left) has a 15-carbon farnesyl group attached to the C-terminal by farnesyltransferase 
enzyme (FTase), and the mature lamin B1 protein remains permanently farnesylated. Lamin A precursor (red, right) 
is also farnesylated, but the C-terminus is later cleaved by proteolytic enzyme ZMPSTE24. The mature form of lamin 
A lacks a C-terminal farnesyl group. Lamin C is also a product of the LMNA gene through alternative splicing, but is 
never farnesylated. 
1.2 Myelin 
White matter composes up to 40% of the mature human brain (27), of which myelin is the 
major component. Composed of sheaths made from many phospholipid bilayers wrapped around 
axons in the brain and spinal cord, its purpose is to enable saltatory transmissions of nerve impulses 
along the lengths of the neurons (Figure 1.4A and B). In the central nervous system (CNS), myelin 
is produced by a special type of cell known as oligodendrocytes and is a modification of 
oligodendrocyte cell membranes. High concentrations of myelin and oligodendrocytes can be 
found in the major white matter tracts of the central nervous system, such as the corpus callosum, 
which connects the left and right hemispheres of the brain and acts as a popular anatomical 
landmark due to its size and ease of identification. 
 
Mature lamin A
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Mature Lamin B1 Pre-lamin A
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Lamin B1 precursor Lamin A precursor
LMNB1 LMNA
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Figure 1.4: Myelination and oligodendrocytes. 
(A) Electron micrograph image of mouse corpus callosum shows cross sections of axons and their myelin sheaths. 
Scale bar: 1µm. (B) Illustration of an axon surrounded by myelin wrapping. (C) A single mature oligodendrocyte 
(green) is capable of myelinating multiple axons. 
1.2.1  Oligodendrocytes 
Oligodendrocytes, along with astrocytes and microglia, comprise a group of cells known 
as glia. Glia compose the majority of cells in the nervous system, and they provide structural 
support, signaling, and safety for neurons (28). Oligodendrocytes themselves make up 20% of the 
cells in the brain (29), and are responsible for myelination in the CNS, as opposed to Schwann 
cells in the peripheral nervous system. Depending on the region of the CNS, one oligodendrocyte 
is capable of myelinating anywhere from a single axon to dozens of axons (Figure 1.4C) (30). 
They differentiate from multipotent cells known as oligodendrocyte progenitor cells (OPCs), 
which are in turn derived from the neural tube epithelium during early gestation (31). OPCs are 
Axon
Myelin
Created with BioRender
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C
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defined by their ability to proliferate and migrate, but not myelinate, as well as their expression of 
surface markers such as platelet-derived growth factor receptor alpha (PDGFRα) and NG2 
proteoglycan (32). Cessation of OPC proliferation and migration is necessary to differentiate into 
mature (a.k.a. myelinating) oligodendrocytes, but artificially arresting OPC proliferation is not 
sufficient to induce differentiation in vivo (33). Proper signaling pathway activation is required for 
successful differentiation, such as decreased Wnt/beta-catenin signaling (34), decreased Notch 
signaling (35), and increased ERK-1/2 levels (36). Epigenetics, non-coding RNAs, and external 
stimuli have also been implicated in regulating OPC differentiation (37-39).  
1.2.2  Proteins involved in myelination 
Axons in the nervous system are wrapped in extensions of the oligodendrocyte cell 
membrane known as myelin. In mice, myelination starts at birth in the spinal cord, and is generally 
completed at around two months of age (28). Myelination in the human CNS takes years and is 
generally completed during the second decade of life (31). Proper formation of myelin requires 
significant investment of lipids, proteins and enzymes, a few of which will be covered here. 
Proteolipid protein 1 (PLP1), is a major component of myelin, a transmembrane protein 
that constitutes 50% of the myelin protein in the CNS (40). It most likely binds to other copies of 
itself spaced along the myelin membrane in order to aid folding, compaction, and maintenance of 
myelin’s multilayered structure (41). It is coded by the PLP1 gene on Xq22, predominantly 
expressed in oligodendrocyte lineage cells, and is highly conserved across humans, apes, and 
rodents. Mutations of PLP1 are associated with dysmyelinating neurodegenerative disorders such 
as Pelizaeus-Merzbacher disease and spastic paraplegia type 2 (42, 43). 
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Myelin basic protein (MBP), constituting 30% of the CNS myelin protein (40), is the 
second most common protein component of myelin. Coded for by the MBP gene in 18q23, MBP 
is highly cationic and assists with myelin wrapping by interacting with negatively-charged 
phospholipid groups as well as PLP1 in the membrane (40, 44). Absence of MBP in mice leads to 
severe CNS hypomyelination, resulting in a shivering phenotype and an early death (45, 46). 
Autoimmunity to MBP in humans is also linked to pathogenesis of multiple sclerosis (MS) (47). 
Myelin oligodendrocyte glycoprotein (MOG) is a transmembrane adhesion molecule that 
is found exclusively in the CNS (48). It is hypothesized to homodimerize along the myelin sheath 
to maintain tight wrapping, similar to PLP (49). Autoimmunity to MOG antigens is also implicated 
in the onset of MS (49). 
Myelin associated glycoprotein (MAG), another transmembrane glycoprotein, is found in 
both the CNS and peripheral nervous system (50). It likely plays important roles in glial-axon 
membrane interactions (51), therefore being an important target for neuronal regeneration or 
remyelination after CNS injury. 
2',3'-Cyclic-nucleotide 3'-phosphodiesterase (CNPase) is a membrane-anchored myelin 
enzyme that is exclusively and highly expressed by oligodendrocytes (52). In fact, it is the earliest 
known myelin-specific protein expressed by oligodendrocytes (53). Its exact physiological roles 
remain unknown, but studies involving the disruption of the Cnp gene in mice show that it is of 
great importance to myelin stability and neuronal health. Overexpression of CNPase inhibits MBP 
accumulation and myelin compaction (54), and is associated with age-dependent myelin 
degradation (55). Total absence of CNPase leads to age-dependent axonal degeneration but 
without myelin disruption (56, 57).  
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Lipids constitute the vast majority of myelin: 70% to 85% of myelin’s dry weight is 
composed of lipid. White matter is named as such because its lipid content gives it a whitish 
appearance. The most common lipid in myelin, galactocerebroside, is synthesized in 
oligodendrocytes and Schwann cells (58, 59). Krabbe disease, a rare and fatal lysosomal storage 
disease, arises from mutations of the gene that codes for galactocerebrosidase, GALC (60). Lacking 
this enzyme leads to a buildup of unmetabolized lipids and severe demyelination. Cholesterols are 
also important for the maintenance of cell membranes (61), and the brain is particularly rich in 
cholesterol: 25% of the body’s total cholesterol content could be found within the brain (62), of 
which 80% is in myelin (63, 64). Perturbation of myelin synthesis in mice leads to ataxia and 
tremor phenotypes (64). Interruption of cholesterol or lipid synthesis pathways without altering 
myelin protein levels could subsequently lead to demyelination. 
1.2.3  Demyelinating disorders 
Disorders in myelin production or maintenance are called demyelinating disorders. The 
most prominent demyelinating disorder is MS, affecting close to 1 in 1,000 people in North 
America and Europe, and is the foremost disabling disease in young adults (65). MS is an 
inflammatory disorder in which immune cells attack and destroy myelin sheaths surrounding axons 
in the CNS, resulting in an impairment of neuronal transmissions and symptoms such as muscle 
weakness, optic neuritis, and cognitive impairment (66). Once damage to myelin has occurred, 
adult humans only have a very limited capacity to stimulate the remyelination in damaged tissue.  
A particular subset of demyelinating disorders is known as leukodystrophies, a group of 
rare diseases caused by genetic abnormalities that lead to aberrant production or destruction of 
myelin. Leukodystrophies include Canavan disease (67), Pelizaeus-Merzbacher disease (42, 68) 
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and adult-onset autosomal dominant leukodystrophy (ADLD) (69), each with different etiologies 
and ages of onset ranging from childhood to middle age. In all cases, treatments may improve 
quality of life, but there are currently no cures. 
1.3 Laminopathies 
Diseases from lamin mutations or misregulation are collectively known as laminopathies. 
LMNA-linked laminopathies include a wide variety of disorders in a wide variety of tissues and 
organ systems such as cardiomyopathy (70, 71), Emery-Dreifuss Muscular Dystrophy (72), 
Charcot-Marie-Tooth disease (73), Familial Partial Lipodystrophy (74), and the accelerated aging 
disorder Hutchinson-Gilford Progeria Syndrome (75). In contrast, B-type lamins are not associated 
with as many diseases as their A-type counterparts. LMNB2 mutations have been associated with 
Acquired Partial Lipodystrophy (76), and the overexpression of LMNB1 leads to ADLD (77). 
1.3.1  Autosomal Dominant Leukodystrophy (ADLD) 
ADLD (OMIM #169500) is a rare, progressively severe, and fatal demyelinating 
laminopathy with an average age of onset at the fourth or fifth decade of life. Patients with ADLD 
lose the protective myelin sheath surrounding their axons, resulting in muscle weakness, loss of 
autonomic function, paralysis, and eventually death (78). Distinct from MS in its severity, ADLD 
demyelination also occurs in a symmetrical fashion unlike the multifocal lesions commonly found 
in MS patients (79). We have further shown that lamin B1 overexpression in oligodendrocytes 
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leads to defects of lipid synthesis, eventually resulting in a severe age-dependent demyelinating 
phenotype characteristic of ADLD (80). 
 
Figure 1.5: Tandem head-to-tail duplications of LMNB1 are associated with ADLD. 
 
The established etiology of ADLD is that a genomic duplication of LMNB1 leads to its 
overexpression (Figure 1.5). Molecular analyses of genomic duplications involving LMNB1 
attribute non-homologous end joining, microhomology-induced break replication, or other 
replication-based mechanisms as the cause of duplications (81-83).  
Recently however, we have identified a few families with ADLD that do not have a LMNB1 
duplication (84). These families have large deletions upstream of the LMNB1 locus instead, 
varying in size from 250 kb to 672 kb in size. The current hypothesis for the mechanism of LMNB1 
overexpression is that the deleted regions include a topological associating domain (TAD) 
boundary. TADs are sections of the genome enriched with frequently interacting DNA-DNA 
complexes that form within a region as a result of a chromosome’s three-dimensional organization 
within the nucleus (85), identified through a process known as chromosome conformation capture 
(86). The exact mechanism of TAD formation remains poorly understood, but they often form 
within chromatin loops between lamina-associated domains at the nuclear periphery (87). TAD 
boundaries sequester one TAD from the next, so that the regulatory mechanisms such as enhancers 
in one TAD do not interact with genes present in a different TAD. Perturbations of TAD 
GRAMD3 PHAX LMNB1
ALDH7A1
Wild-type
LMNB1 Duplication
(ADLD)
chr5
chr5
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boundaries could lead to aberrant chromatin interactions, and in the case of genomic deletions 
upstream of LMNB1, gene overexpression (88). 
1.4 Public Health Significance 
Laminopathies as a whole represent a wide variety of diseases that can affect nearly every 
tissue and organ system within the human body. One such laminopathy, the demyelinating disorder 
known as ADLD, has significant overlap with more prevalent demyelinating disorders such as MS 
(89). However, MS is a multifactorial disease resulting from the complex interactions of many 
genetic and environmental factors over long periods of time. Researching molecular pathways 
within rare Mendelian-inherited disorders involving one gene and one disease with high 
penetrance, such as ADLD, is more straightforward than disentangling complex, multifactorial 
diseases encompassing dozens of genes with varying contributions to the phenotype. Finding an 
effective treatment for white matter injuries would be of significant public health value. 
Impairment of oligodendrocyte maturation through hypoxia-ischemia and infection/inflammation 
during gestation can lead to cerebral white matter injury at birth, common in preterm neonates 
(90). In the aging brain, white matter is altered and degraded in dementias such as Alzheimer’s 
disease (91, 92).  Even though ADLD is very rare (fewer than 30 known affected families 
worldwide), interventions designed to halt disease progression may also be applied to MS, white 
matter injuries, and other demyelinating disorders. The role of LMNB1 also extends far beyond 
nuclear shape maintenance. For example, LMNB1 expression can regulate cell proliferation rates 
and senescence (93), with ramifications to cellular aging processes (94). In addition, lamin B1 
degradation through autophagy has been proposed as a possible cellular defense mechanism 
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against carcinogenesis (95). Therefore, studying the interactions between lamins and their 
significance in white matter development and oligodendrocyte differentiation has far-ranging 
implications for public health. 
1.5 Summary 
The nuclear lamina functions to maintain nuclear shape and structure as well as regulate 
gene expression. Intermediate filaments known as lamins are organized in to two types: A-type 
and B-type. Each have diverse functions within various tissues and undergo distinct post-
translational modifications. Although their chemical makeup has been well-documented, the 
organization of the lamina at the nuclear periphery has been a mystery until now. 
Glial cells known as oligodendrocytes are responsible for generating the protective myelin 
sheaths around axon fibers in the CNS. In ADLD, these cells are particularly affected, leaded to 
age-dependent demyelination. Overexpression of LMNB1 in oligodendrocytes leads to ADLD-like 
symptoms in mice due to defects in lipid synthesis pathways. However, no studies have been done 
to explore the role of lamin B1 specifically in the proliferation, differentiation, or function of 
oligodendrocytes. 
Mutations of lamin genes or changes in their expression often lead to diseases collectively 
known as laminopathies. Laminopathies involving the LMNA gene, which codes for both A-type 
lamins (A and C), are most often studied due to the wide variety of syndromes affecting a multitude 
of organ systems, including cardiomyopathy, muscular dystrophy, lipodystrophy, and progeria. In 
contrast, laminopathies involving B-type lamins are less numerous. One such laminopathy is 
ADLD, a severe and fatal demyelinating disorder caused by the overexpression of LMNB1, the 
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gene coding for lamin B1. Genomic duplications in 5q23 surrounding LMNB1 are canonically 
accepted to be the mechanism for overexpression that causes ADLD. However, there is mounting 
evidence from my research that simply an extra copy of this gene is not the only factor needed to 
cause overexpression leading to ADLD. 
My thesis work focuses on answering the following questions: 
1.)  What is the structural organization of A and B-type nuclear lamins at the nuclear 
periphery? 
2.) What role does lamin B1 play in oligodendrocyte development and maturation? 
3.) How do genomic duplications, deletions, or rearrangements involving LMNB1 lead to 
ADLD pathogenesis? 
To address these questions, we have used super-resolution microscopy and biochemical 
analyses on human and murine cells in culture, generated transgenic mice with Lmnb1 knocked 
out in oligodendrocytes, and compared copy number variants of families with ADLD against their 
clinical outcomes. This work will provide new paradigms for the nuclear organization and genomic 
regulation of LMNB1. 
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2.0 Hypotheses and Specific Aims 
The overall aim of my dissertation research is to evaluate the function of lamin B1 in 
development and disease: its role within the nuclear envelope maintaining nucleus shape and 
stability, its function within oligodendrocytes, and finally tissue-specific genome regulation 
affecting its expression. 
Aim 1: Decipher the structural and functional organization of the nuclear lamina. 
Although the nuclear lamina is well-studied, how the lamin proteins are organized is still 
unknown. I hypothesize that the organization of individual lamin species will indicate their 
functions in maintaining envelope nuclear shape. 
Methods: In collaboration with Dr. Yang Liu at the University of Pittsburgh and Dr. Kris 
Dahl at Carnegie Mellon University, we have used a combination of approaches including super-
resolution microscopy, conventional fluorescent microscopy, and various biochemical and 
biophysical techniques to determine the spatial organization of A-type and B-type lamins at the 
nuclear periphery of mouse and human cells. We will determine whether the organization of these 
individual lamin components provide insights into their distinctive functional roles. 
Aim 2: Evaluate the role of lamin B1 in mouse oligodendrocyte development. 
The function of lamin B1 specifically in oligodendrocytes has not been studied in detail. I 
hypothesize that the loss of Lmnb1 in mouse oligodendrocytes will adversely affect their 
development and proliferation, leading to myelination defects in the CNS. 
Methods: Using cre-lox recombination, I have generated mice with Lmnb1 knocked out in 
mature oligodendrocytes. We will characterize the behavior of these mice, the expression of 
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myelin-associated genes at different time-points, and the properties of oligodendrocyte lineage 
cells using behavioral as well as biochemical and immunofluorescence analyses. 
Aim 3: Study the role of genomic rearrangements involving LMNB1 in the pathogenesis of 
ADLD. 
Although LMNB1 duplications are causative for ADLD, we have now identified families 
with ADLD without duplicated LMNB1, as well as families with LMNB1 duplications but without 
ADLD. Different types of copy number variations surrounding LMNB1 can have distinct 
consequences in terms of ADLD pathogenesis, so I hypothesize that there is a novel genomic 
regulatory pathway of LMNB1 that provides a comprehensive mechanism predicting the various 
disease outcomes. 
Methods: A custom microarray-based comparative genomic hybridization assay was used 
determine the copy number variations surrounding the LMNB1 gene in 5q23.2. Duplication 
junctions were then identified, and insertion sites of the duplications mapped were back to the 
genome. The size and nature of these variations are matched with their clinical outcomes. We hope 
to narrow down a genomic region of interest for further study into the regulatory mechanisms of 
LMNB1. CRISPR knockout experiments could then be designed for future studies.  
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3.0 The Structural and Functional Organization of the Nuclear Lamina 
3.1 Introduction 
Studies utilizing optical microscopy and cryo-electron tomography (cryo-ET) to visualize 
the structural organization of lamins in mammalian cells revealed the presence of a meshwork 
structure, and indicated that each component formed separate but interacting meshworks (13, 96).  
However, no distinct spatial organization of the individual lamin subtypes across the nuclear 
envelope was reported at the time. It has been known that the depletion of specific lamin species, 
A-type or B-type, leads to disparate nuclear abnormalities in vitro. The removal of B-type lamins 
leads to an increase in the frequency of nuclei with blebs (13, 14), but the removal of A-type lamins 
leads to nuclear envelope ruptures and defective mechanotransduction (8, 97). While the effects 
of disease-causing LMNA mutations on nuclear shape and function has been well studied (98), the 
same cannot be said about LMNB1 overexpression in vitro. 
Previous research into the organization of the lamina at the nuclear periphery has been 
conducted with the use of electron microscopy (EM) (96, 99-101). While EM’s resolution is a 
staggering 0.2 nm, a significant drawback is its inability to simultaneously image and discriminate 
different protein species. Limited protein differentiation could be achieved using immunogold 
particle labeling with variable-sized gold nanoparticles (96), but the size of the antibody-particle 
complexes (up to 30 nm) and their signal density compaed to fluorescent markers make 
differentiating closely-associated proteins like A-type and B-type lamins nearly impossible. On 
the other hand, conventional fluorescence microscopy can easily differentiate protein species 
simultaneously with the use of fluorophore-conjugated antibodies. However, its spatial resolution 
 18 
is diffraction-limited to around 200 nm thanks to the properties of visible light wavelengths. This 
is much too large to resolve proteins that are potentially less than 15 nm apart. 
I aim to determine whether the A and B type lamins exhibit any distinct spatial 
organization, and if so, whether this was reposonsible for the disparate consequences from 
depletion of the two lamin subtypes. To achive this aim, we used a combination of a super-
resolution microscopy technique known as stochastic optical reconstruction microscopy 
(STORM), biochemical, and biophysical methods. STORM combines the ability to resolve past 
the diffraction limit while differentiating multiple proteins simultaneously. It offers the best spatial 
resolution of ~20 nm using relatively simple instruments, and the resolution of the final 
reconstructed image can be improved by an order of magnitude (102). STORM and biophysical 
studies were carried out in collaboration with Prof. Yang Lui’s group at the University of 
Pittsburgh and Prof. Kris Dahl’s group at the Carnegie Mellon University. 
3.2 Materials and Methods 
3.2.1  Cell Culture 
Primary MEFs (Wild-type and TRE-FLAG-LMNB1;ROSA26-rtTA cells were isolated in 
lab from E13.5 embryos, Lmnb1CS/CS cysteine-to-serine mutant (23), Lmnb1-/- (9) and Lmna-/- (103) 
cells were from the lab of S.G. Young), human fibroblasts, and HeLa cells were cultured in 
complete DMEM (high glucose DMEM (Corning) supplemented with 10% FBS (Fisher), 2mM 
L-glutamine (Millipore), and 1% Penicillin streptomycin (Hyclone)). Cells were incubated in a 
humidified chamber at 37°C and 5% CO2. When cells reached 90-100% confluence, they were 
 19 
trypsinized, diluted, and re-plated using fresh media. For calyculin A and blebbistatin treatments, 
HeLa cells grown on coverslips were treated with 0.1 and 1 nM calyculin A (Sigma #508226) for 
30 minutes, or 10, 50, and 100 μM blebbistatin (Sigma #203389) for 2 hours at 37°C and 5% CO2. 
Cells were washed and fixed in 4% paraformaldehyde solution in PBS immediately after treatment. 
Lamin B1 overexpression was induced in TRE-FLAG-LMNB1;ROSA26-rtTA transgenic MEFs by 
supplementing growth medium with 2 μg/mL doxycycline hyclate (Sigma). 
3.2.2  STORM imaging and analysis 
Cells for STORM imaging were prepared as previously described (104). Rabbit anti-lamin 
B1 (Abcam #ab16048) were diluted 1:600 and/or mouse anti-lamin A/C (Cell Signaling #4777) 
were diluted 1:300 in PBS + 3% BSA, and incubated on the cells overnight at 4°C. The next 
morning, cells were washed with PBS three times for 5 minutes each at room temperature. 
Secondary antibodies were diluted in PBS + 3% BSA and incubated with the cells for 2 hours at 
room temperature in the dark. Unconjugated secondary antibodies (Jackson ImmunoResearch 
#711-005-152 and #715-005-150) were conjugated with AlexaFluor (AF) 647 (Thermo Fisher 
Scientific, #A20006) in the lab of Dr. Yang Liu, University of Pittsburgh. AF647-conjugated 
secondary antibodies were used for single-color STORM imaging. For two-color STORM imaging 
based on dye pairs, secondary antibodies labeled with activator-reporter dye pairs (AF405-AF647, 
Cy2-AF647) were used. AF405-AF647 conjugated donkey anti-mouse secondary antibody was 
used to label lamin A/C, and Cy2-AF647 conjugated donkey anti-rabbit secondary antibody was 
used to label lamin B1. For the dye-switch experiment, AF405-AF647 conjugated donkey anti 
rabbit secondary antibody was used to label lamin B1, and Cy2-AF647 conjugated donkey anti 
mouse secondary antibody was used to label lamin A/C. Immediately before imaging, the buffer 
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was switched to STORM imaging buffer (10% w/v glucose (Sigma-Aldrich), 0.56 mg/mL glucose 
oxidase (Sigma-Aldrich), and 0.17 mg/mL catalase (Sigma-Aldrich)). For single color imaging, 
0.14M β-mercaptoethanol (Sigma-Aldrich) was used, and for two-color imaging, 0.1M 
mercaptoethylamine (MEA, Sigma-Aldrich) was used. 
Single-color STORM imaging was performed on a custom-built system using an Olympus 
IX71 inverted microscope frame with a 60X oil objective. Fluorescent beads (0.1 μm diameter, 
Fisher Scientific #F8803, excited using 488 nm laser) are used as fiduciary markers on the 
coverslip to correct for 3-D system drift every 200 frames. Two-color STORM images using dye 
pairs were acquired on a commercial imaging system (N-STORM, Nikon Instruments). The 
samples were periodically activated with a sequence of 405nm, 488nm laser pulses and then 
imaged with the 647nm laser. In each switching cycle, the activation laser was turned on for 1 
frame, followed by 3 frames of illumination with the red imaging laser. A total of 40,000 frames, 
including 10,000 activation frames and 30,000 imaging frames for each channel, were acquired at 
an exposure time of 20 milliseconds per frame. Imaging frames immediately following an 
activation pulse were recognized as controlled activation events and a color was assigned 
accordingly. A crosstalk subtraction algorithm was used to subtract the non-specific activation 
signal (105). 
Nuclei were imaged at the equator for measuring lamina thickness and relative localization. 
For lamina surface imaging, the bottom surfaces of nuclei were imaged in order to minimize 
curvature artifacts. The reconstruction of a super-resolution image and Gaussian clustering were 
performed using a custom program written in Matlab 2015 (MathWorks), as previously described 
(106). The degree of co-localization was calculated using Clus-DoC algorithm (107) and defined 
as the degree of co-localization in lamin A/C and lamin B1 with respect to the combined lamin 
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A/C and lamin B1. For measuring lamina thickness, the nuclear periphery of the super-resolution 
image was automatically divided into numerous small segments at a length of ~50 nm. Intensity 
peaks were measured along the steepest gradient perpendicular to the nuclear envelope, and 
averaged. The intensity profile was plotted as distance (x axis) versus normalized lamin intensity 
(y axis), and thicknesses were defined as the full width at half maximum (FWHM).  
3.2.3  Isolation of nuclei 
Low-passage cells were seeded in 100-mm tissue culture dishes (Thermo BioLite) and 
grown to 90% confluence. Nuclei were isolated as previously described (108), with modifications. 
The cells were washed once with 3 mL ice-cold PBS, then scraped down with 1 mL cold PBS into 
1.5 mL microcentrifuge tubes. Samples were centrifuged at 10,000xg for 15 seconds at 4°C, and 
the supernatants were discarded. Cell pellets were resuspended in 1 mL cold PBS+IGEPAL (1x 
PBS + 0.1% IGEPAL CA-630 (Sigma) + protease inhibitors), triturated 5x on ice with a 1000 μL 
pipet tip, and 100 μL transferred into new microcentrifuge tubes as the whole cell fraction. 
Remaining volumes were centrifuged at 10,000xg for 15 seconds at 4°C. Supernatants were 
transferred to new microcentrifuge tubes labeled “cytosol.” Pellets were resuspended in 1 mL 
PBS+IGEPAL, then centrifuged at 10,000xg for 15 seconds at 4°C, and the supernatants were 
discarded. Remaining pellets were used for sequential protein extractions. Cytosol samples were 
centrifuged at 10,000xg for 1 minute at 4°C, then 300 μL of the supernatant was transferred to new 
microcentrifuge tubes as the clean cytosolic fraction. 
22 
3.2.4  Sequential extraction of nuclear envelope proteins 
Subfractionation of nuclear proteins was performed as previously described (109). Nuclear 
pellets were resuspended in 300 μL nuclear isolation buffer (10 mM HEPES pH 7.4, 2 mM MgCl2, 
25 mM KCl, 250 mM sucrose, 1 mM DTT, protease inhibitors). 50 μL of each sample were 
transferred to new microcentrifuge tubes as the “whole nuclei” fraction. Samples were sonicated 
on ice with two 5 second pulses at 10 μm amplitude, then centrifuged at 20,000xg for 5 minutes at 
4°C. The supernatants were transferred to new microcentrifuge tubes as the “Sonication” fraction. 
Pellets were resuspended in 250 μL nuclear extraction buffer (20 mM HEPES pH 7.4, 1 M NaCl, 
protease inhibitors), and incubated for 20 minutes at room temperature with end-over-end rotation. 
After incubation, samples were centrifuged at 20,000xg for 5 minutes at 4°C, and the supernatants 
were transferred to new microcentrifuge tubes as the “1 M NaCl” fraction. Extractions were 
repeated on the pellets using 250 μL nuclear extraction buffer with 2% v/v Triton X-100, 4 M urea, 
and then 8 M urea in sequential incubations. All protein extracts were stored at -80°C until ready 
for immunoblotting. 
3.2.5  RNAi knockdown of lamin genes 
6-well plates were seeded with 4x105 HeLa cells/well in DMEM without serum or 
antibiotics and transfected for 24 hours with 50 nM siRNA (Scrambled: ThermoFisher #4390843, 
LMNB1: ThermoFisher #S8224 and #S8225, LMNA: ThermoFisher #S8221) using RNAimax 
transfection reagent (ThermoFisher) diluted in OptiMEM (Gibco). The next day, cells were refed 
with complete DMEM and incubated for another 24 hours, after which proteins were extracted 
using T-PER with protease inhibitors (Thermo), or immunocytochemistry was performed. 
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3.2.6  Immunofluorescence staining and analysis 
Cells were seeded on glass coverslips and incubated at 37°C and 5% CO2 until they were 
70-90% confluent. Cells were washed with DPBS (Sigma), then fixed with 4% formaldehyde (Ted 
Pella) in PBS for 15 minutes at room temperature. After three washes of 5 minutes each with PBS, 
blocking and permeabilization was performed simultaneously with PBS + 5% normal donkey 
serum (Jackson ImmunoResearch) + 0.3% Triton X-100 (Sigma) for 1 hour at room temperature. 
Primary antibodies were diluted in PBS + 1% BSA (Sigma) + 0.3% Triton X-100 and incubated 
with the cells overnight at 4°C. Primary antibodies and dilutions are listed in Appendix A. The 
next morning, primary antibody dilutions were discarded, and cells were washed with PBS three 
times for 5 minutes each at room temperature. FITC-conjugated donkey anti-rabbit (Jackson 
ImmunoResearch #711-095-152) and Cy3-conjugated donkey anti-mouse (Jackson 
ImmunoResearch #715-165-150) secondary antibodies were each diluted 1:350 in PBS + 1% BSA, 
and incubated with the cells for 1 hour at room temperature in the dark. Cells were washed three 
times for 5 minutes each in PBS, then mounted onto glass microscope slides using Vectashield 
antifade mounting medium with DAPI (Vector Laboratories). 
Wide-field microscopy images were acquired of immunofluorescently-labeled nuclei on a 
Leica DM5000B upright microscope with a 40x NA 0.75 objective, a 63x NA 1.40 oil immersion 
objective, and a Leica DFC310 FX digital camera. Confocal images were acquired on an Olympus 
FV1000 inverted microscope using a 60x NA 1.40 low chromatic aberration oil immersion 
objective and integrated digital camera. ImageJ (FIJI) was used to measure nuclear 
periphery/center (P/C) fluorescence intensity ratios and fluorescence intensity profile plots from 
confocal images. P/C ratios were calculated by measuring the mean gray value of the nuclear 
periphery and dividing it by the mean gray value of the nuclear center in red and green channels 
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separately. Average P/C ratios from at least 15 nuclei per genotype (WT versus Lmnb1CS/CS MEFs) 
were plotted with standard errors. Fluorescence intensity profile plots were generated by drawing 
a line across the midline of a nucleus and plotting gray value versus distance. Nuclear bleb ratios 
were calculated by counting the number of nuclei with one or more blebs in wide-field images, 
and dividing it by the total number of nuclei imaged. Blebs were considered devoid of a lamin if 
its intensity was less than 50% of the intensity throughout the nuclear body after background 
fluorescence subtraction. At least 150 nuclei per cell type and treatment were counted in 15 to 20 
random, non-overlapping fields. Partially-visible nuclei at the field edges were ignored. 
3.2.7  Immuno-TEM and analysis of mouse embryonic fibroblasts 
MEFs were grown to confluency in 24 well tissue culture plates, washed once with 37°C 
PBS then fixed with 4% paraformaldehyde, 0.1% glutaraldehyde in PBS for 1 hr at RT.  Cells 
were washed 3 x with PBS then permeabilized for 30 min at RT with 0.25% Triton X-100 in PBS. 
Cells were washed 3x in PBS then blocked in 5% normal goat serum in PBS for 45 min. Cells 
were washed 2x for 15 min in 0.5% BSA, 0.1% Tween-20 in PBS (BT-PBS) then incubated with 
individual anti-lamin primary antibodies (1:25 dilution in BT-PBS) 18 hrs while shaking at 4°C. 
Cells were washed 5 x in BT-PBS 10 min each, then 6 nm gold-conjugated antibodies (goat anti-
rabbit or goat anti-mouse, (Jackson ImmunoResearch, West Grove, PA) diluted 1:10 in BT-PBS) 
were incubated for 18 hr at 4°C while shaking. Following 3x 15 min washes with BT-PBS, and 
additional 3 x 15 min washes in PBS, labeled cells were fixed with 2.5% glutaraldehyde in PBS 
for 1 hr.  Cells were then washed 3 x in PBS, post-fixed in 0.5% osmium tetroxide in dd-H2O for 
30 min. Following 3 washes in PBS, cells were then dehydrated through a 30-100% ethanol series 
then several changes of Polybed 812 embedding resin (Polysciences, Warrington, PA). Cultures 
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were embedded in by inverting Polybed 812-filled BEEM capsules on top of the cells.  Blocks 
were cured overnight at 37°C, then cured for two days at 65°C. Monolayers were pulled off the 
TC plate and ultrathin en face sections (60 nm) of the cells were obtained on a Riechart Ultracut 
E microtome, post-stained in 4% uranyl acetate for 10 min and 1% lead citrate for 7 min. Sections 
were viewed on a JEOL JEM 1011 transmission electron microscope (JEOL, Peabody MA) at 80 
KV. Images were taken using a side-mount AMT 2k digital camera (Advanced Microscopy 
Techniques, Danvers, MA).  
To calculate the distance between lamin A/C to chromatin boundary, we first defined the 
positions for nanogold particles and chromatin boundary. To define the position for the nanogold 
particles, we processed the images as follows: (1) invert the grayscale value of the EM image;  (2) 
perform image smoothing using difference of Gaussian filter; (3) find the local maxima as the 
position of nanogolds; (4) the central positions of the identified nanogolds along the nuclear 
membrane is retrieved by finding a curve with minimum deviation to the positions of nanogold by 
adapting a 2nd order polynomial function; (5) fit the accumulated number of the segmented 
nanogold particles along the central trajectory of nanogolds with a Gaussian function and the peak 
position is used as the position for nanogolds (as shown in Figure 3.3C and D). To define the 
position for chromatin boundary, we first remove the segmented nanogold particles as described 
above from the EM image, plot the average intensity profile of the remaining EM image along the 
central trajectory identified above and the peak position of the intensity profile is used as the 
position for chromatin boundary. The distance between the positions of lamin A/C and chromatin 
boundary, and lamin B1 and chromatin boundary was then calculated. 
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3.2.8  Micropipette aspiration 
HeLa cells were seeded into glass-bottomed dishes in complete DMEM and cotransfected 
with DsRed-LMNA and GFP-LMNB1 plasmids using Lipofectamine3000 (ThermoFisher), 
according to the manufacturer’s protocol for double transfections. Cells were imaged and 
manipulated 48 hours post transfection, and 0.17 mg/mL of Hoescht 33342 (ThermoFisher) was 
added to the media to visualize DNA. Live cell imaging in micropipette aspiration experiments 
was performed on a Leica DMI6000 inverted microscope with a 40x NA 1.25 oil immersion 
objective, and a Leica DFC350 FX digital camera. Micropipettes were pulled from 1 mm glass 
capillary tubes using a PMP102 Micropipette puller (Microdata), and the micropipette used for the 
study was 5.8 μm in diameter. Narishige pipette holders and micromanipulators were used to 
approach the cells of interest, and nuclei were aspirated directly from intact cells. Aspiration 
pressure was applied via a syringe to obtain aspirations of different lengths. Analysis of intensities 
and lengths was performed in ImageJ. The intensity at the aspiration tip, which is the curved 
section of the nuclear lamina farthest down the pipette, was normalized to the intensity of the non-
aspirated region of the lamina. Note that the intensity of the DsRed-lamin A/C was 150-200% 
brighter than that of GFP-lamin B1. 
3.2.9  Immunoblotting 
Protein concentrations were measured using the Pierce BCA protein assay kit 
(ThermoFisher). 70 μg of protein was mixed with 4x Laemmli sample buffer (Bio-Rad) and boiled 
for 10 minutes at 95°C. For sequential nuclear extraction samples, 18 μL of each fraction was 
mixed with 6 uL of 4x Laemmli sample buffer, and boiled for 10 minutes at 95°C. Protein samples 
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were then separated using SDS-PAGE, transferred onto nitrocellulose membranes (Bio-Rad), then 
blocked for 1 hour at room temperature with Odyssey blocking buffer (LI-COR Biosciences). 
Primary antibodies were diluted in at the following concentrations: Membranes were hybridized 
with primary antibodies diluted in Odyssey blocking buffer + 0.1% Tween 20 (Fisher) overnight 
at 4°C with gentle shaking. Primary antibodies used and their dilutions are listed in Appendix A. 
The next morning, membranes were washed three times for 10 minutes each with TBS-T (TBS + 
0.1% Tween 20), and incubated with goat anti-mouse 680LT (LI-COR #926-68020) and donkey 
anti-rabbit 800CW (LI-COR #926-32213) secondary antibodies diluted 1:10000 in Odyssey 
blocking buffer + 0.1% Tween-20 for 1 hour at room temperature in the dark. After three 10-
minute washes in TBS-T, membranes were scanned, imaged, and quantified using the LI-COR 
Odyssey CLx infrared scanner and Image Studio software (LI-COR Biosciences). 
3.2.10  Statistical analysis 
Two-sided t-tests were used to calculate statistical significance between two groups. For 
micropipette aspiration comparisons, two-way ANOVAs were used followed by Sidak’s multiple 
comparisons test. For sequential protein extractions, lamin signal percentages were arcsine 
transformed prior to statistical analysis. Chi-squared tests were used to assess statistical 
significance of blebbing ratios. Bleb versus nuclear lamin intensity differences were compared 
using Wilcoxon matched-pairs signed rank test. A p-value ≤ 0.05 was considered statistically 
significant. The following convention for representing p values was followed: *p ≤ 0.05, **p ≤ 
0.01, ***p ≤ 0.001. All error bars represent standard error unless otherwise specified. Data were 
graphed and analyzed in Microsoft Excel 2016 and GraphPad Prism 7. 
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3.3 Results 
3.3.1  Differential localization and membrane association of lamin B1 versus lamin A/C
To visualize the spatial relationship between lamin A/C and B1, we used two-color 
STORM imaging carried out by Prof. Yang Liu’s group at the University of Pittsburgh. Cells were 
immuno-stained with primary antibodies against nuclear lamina proteins lamin A/C and lamin B1, 
and then with secondary antibodies conjugated with activator–reporter dye pair (110) (Cy2-
AlexaFluor 647 and AlexaFluor 405-AlexaFluor 647). The use of the same reporter dye 
(AlexaFluor 647) eliminates chromatic aberration, which is crucial for the precise localization of 
the two types of lamins. We specifically focused on the equatorial plane of the cell as the superior 
resolution in the x-y axes would allow us to better appreciate differences in spatial localization 
between the lamin A/C and B1 species across nuclear periphery. We discovered that lamin B1 
preferentially localizes closer to the inner nuclear membrane (INM) whereas lamin A/C is 
localized closer toward the nucleoplasm; there is also significant spatial overlap between the A-
type and B-type lamina meshworks. This pattern was consistent across different cell types and 
species including primary mouse embryonic fibroblasts (MEFs) (Figure 3.1A and B), HeLa cells 
(Figure 3.1C and D), and primary human fibroblasts (Figure 3.1E and F). Lamin B1 was localized 
closer to the INM compared to lamin A/C along the entirety of the nuclear periphery.  
To independently test association of lamin B1 with the INM, we subjected isolated MEF 
nuclei to extraction buffers of increasing stringency that sequentially isolate proteins from the 
lipid-bound fractions. We observed that lamin B1 requires more stringent conditions for its release 
into solution. In the two least stringent conditions, 80% of the total lamin A/C is extracted, 
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Figure 3.1: Spatially distinct localization of lamin B1 and lamin A/C. 
STORM images of immunofluorescently-labeled lamin B1 (green) and lamin A/C (red) nuclear proteins in (A) MEF, 
(C) HeLa, and (E) human fibroblast nuclei at their equatorial planes. Scale bar: 2 μm. Rectangles denote inset zoomed
areas. Inset scale bars: 500 nm and 100 nm. (B), (D), and (F) Fluorescence intensity profile plots across the nuclear
envelopes in STORM images. X-axis: distance (nm). Zero distance denotes center of nuclear lamina Y-axis: intensity
(arbitrary units). Inset: Box-and-whisker plot of separation (nm) between lamin A/C and B1 fluorescent intensity
peaks. n = 5 nuclei. Storm imaging carried out by Dr. Jianquan Xu and Prof. Yang Liu, University of Pittsburgh.
compared to only 40% of lamin B1 in MEFs (Figure 3.2A and C). Since A-type and B-type lamin 
proteins have similar percentages of hydrophobic amino acids (lamin A: 32%, lamin C: 33%, lamin 
B1: 34%), differences in extraction profiles are most likely due to differences in membrane 
association and not hydrophobicity. We replicated these results in HeLa cells (Figure 3.2B and D), 
and they are consistent with our STORM imaging data that lamin B1 is more closely associated 
with the INM as compared to lamin A/C. For further confirmation, we carried out electron 
microscopy with immunogold labeling of lamin A/C and B1 proteins (Figure 3.3). These 
experiments clearly demonstrated a more peripheral localization for lamin B1.  
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Figure 3.2: Lamin B1 is more tightly associated with the inner nuclear membrane. 
Representative western blots of sequential nuclear protein extractions in (A) MEF and (B) HeLa cells. (C) 
Quantification of fractional amount of nuclear lamin proteins solubilized in increasingly stringent sequential 
extractions in WT MEFs and (D) HeLa cells. Graphs represent fraction of total lamin B1 and lamin A/C signal in each 
extraction from three independent experiments. Bars, mean ± S.E.M.; *p≤0.05, **p≤0.01; unpaired two-tailed t-test. 
Figure 3.3: Electron microscopy confirms concentric lamin organization. 
Representative electron microscopy images of MEF cells labeled with 6 nm gold nanoparticles conjugated to 
antibodies against (A) lamin A/C and (B) lamin B1. Images were analyzed and profiles generated as described in 
methods section. The representative normalized profile of chromatin boundary vs. (C) lamin A/C and (D) lamin B1 
are shown. Arrows indicate distance between chromatin boundary and lamin profiles. TEM processing and imaging 
courtesy of Donna Stolz, Center for Biologic Imaging. 
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3.3.2  The C-terminal farnesyl group is necessary for lamin B1 localization 
Given that lamin B1 retains its farnesyl group, we sought to test whether this moiety 
might be responsible for its association with the INM and examined MEFs derived from mice 
homozygous for a cysteine-to-serine mutation (Lmnb1CS/CS) in the CAAX domain which inhibits 
Figure 3.4: The C-terminal farnesyl group determines the spatial organization of lamin B1. 
(A) STORM image at equatorial plane of an immunofluorescently-labeled Lmnb1CS/CS MEF nucleus. Scale bar: 2 μm.
Rectangles denote inset zoomed areas. Inset scale bars: 500 nm and 100 nm. Lamin B1 (green), lamin A/C (red). (B)
Fluorescence intensity profile plots across the STORM imaged Lmnb1CS/CS MEF nuclear envelope. X-axis: distance
(nm). Y-axis: intensity (arbitrary units). Inset: Box-and-whisker plot of separation (nm) between lamin A/C and B1
fluorescent intensity peaks from 5 nuclei. (C) Comparison of lamin B1 and lamin A/C intensity peaks separation in
WT vs Lmnb1CS/CS MEFs. n = 5 nuclei. (D) Confocal immunofluorescence images of representative WT and
Lmnb1CS/CS MEF nuclei taken at the equatorial plane. Lamin B1 (green), lamin A/C (red). Scale bar: 10 μm. Dotted
lines depict measurement lengths of fluorescent intensity plots shown in Fig. 3.4E. (E) Fluorescence intensity profile
plots across representative WT and Lmnb1CS/CS nuclei. The sharp peaks at each end of the lamin A/C and WT lamin
B1 plots represent bright peripheral staining. X-axis: measurement distance (μm). Y-axis: fluorescence intensity
(arbitrary units). (F) Comparison of sequential lamin B1 extractions in WT vs. Lmnb1CS/CS cells. Graph represents
fraction of total lamin B1 signal in each extraction from three independent experiments. Bars, mean ± S.E.M;
**p≤0.01, ***p≤0.001; unpaired two-tailed t-test.
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farnesylation of lamin B1 (23). STORM images of Lmnb1CS/CS MEFs showed that lamin B1 was 
no longer localized closer to the INM (Figure 3.4A) and the relative intensity profiles revealed a 
lamin B1 signal completely overlapping with that of lamin A/C (Figure 3.4B and C).  
Figure 3.5: Lack of lamin B1 farnesylation does not affect lamin A/C. 
(A) Diagram of nuclear periphery and nuclear center in a confocal image of a representative WT MEF nucleus at the
equatorial plane. (B) Graph of normalized Periphery/Center (P/C) intensity ratio. The P/C ratio of lamin B1 is
significantly reduced in Lmnb1CS/CS MEFs, whereas lamin A/C is unchanged compared to WT. n = 30 WT, 15
Lmnb1CS/CS. (C) Representative western blot of sequential nuclear protein extractions in Lmnb1CS/CS MEFs. (D)
Comparison of sequential lamin A/C extractions in WT vs. Lmnb1CS/CS cells. Graph represents fraction of total lamin
A/C signal in each extraction from three independent experiments. Bars, mean ± S.E.M.
Confocal microscopy of Lmnb1CS/CS nuclei at their equatorial planes demonstrated an 
abnormal distribution of lamin B1 throughout the nucleus (Figure 3.4D), including abnormally 
high lamin B1 levels in the nucleoplasm, whereas lamin A/C appears to be unaffected (Figure 
3.4E). Quantifying the ratio of fluorescence intensity at the nuclear periphery “P” to the intensity 
at the nuclear center “C” (Figure 3.5A), the P/C ratio of lamin B1 is significantly smaller in 
Lmnb1CS/CS MEFs compared to WT MEFs (Figure 3.5B), whereas lamin A/C ratios remains 
unchanged. We measured extraction of lamin proteins from nuclei isolated from Lmnb1CS/CS 
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MEFs, finding that a striking 89.4 ± 3.1% of the total lamin B1 was extracted in the least stringent 
fraction (Figure 3.4F and 3.5C), compared to 29.6 ± 8.7% in WT cells and is consistent with 
previous results using farnesyltransferase inhibitors (111). Lamin A/C extraction profiles remained 
unchanged across WT and Lmnb1CS/CS cells (Figure 3.5D). These data confirmed the STORM 
imaging results, indicating that the farnesyl group of lamin B1 is required for its proper localization 
to the INM. 
3.3.3  Lamin B1 localization at the nuclear envelope is curvature dependent
Wide-field fluorescence images of WT MEF nuclei revealed a differential localization of 
lamin B1 and lamin A/C at the nuclear rim (Figure 3.6A): in more ellipsoidal nuclei, lamin B1 
intensity was reduced at the poles. We quantified local radius of curvature, R, as a function of 
normalized lamin intensity (Figure 3.7A for methodology) across WT MEF nuclei. The intensity 
profiles of lamin staining with respect to R showed no correlation with lamin A/C, but an 
exceptionally strong correlation with lamin B1 (Figure 3.6B). Regions of lower R had reduced 
lamin B1 intensity and an extrapolation of the fit line to zero lamin B1 intensity suggests that 
curved structures with a radius of less than 1.8 μm would be devoid of lamin B1.  
Alternatively, plotting of lamin intensity versus bending energy of the nuclear envelope 
can be approximated by the equation for a two-dimensional network: 𝐸𝐸𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 = (12 𝜅𝜅 1𝑅𝑅2) (112, 113). 
Since the bending modulus κ is a constant material property, we plot the effective bending energy 
as a function of 1/R2 (Figure 3.7B). Lamin A/C localization is independent of lamina bending 
energy. In contrast, lamin B1 intensity is an extremely strong function of bending energy. An 
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Figure 3.6: Lamin B1 meshwork is curvature and strain-responsive. 
(A) Wide-field fluorescent microscopy images of WT MEF nuclei displaying differential localization of lamin B1 and
lamin A/C across the nucleus. Dashed lines represent major axes. The vertices at the ends of the major axis are defined
as the nuclear poles. Arrowheads point to areas of decreased lamin B1 intensity. Scale bar: 10 µm. (B) Plot of
normalized lamin intensity versus radius of curvature R for 30 points across 17 nuclei, with logarithmic trendlines. At
the x-intercept, R = 1.8 µm. (C) MEFs were doubly transfected with GFP-LMNB1 and DsRed-LMNA plasmids, then
aspirated with a micropipette. Normalized aspiration length, L/D, is defined as the aspirated projection length, L,
divided by the diameter of the micropipette, D. Arrows point to aspiration tip and base. Scale bar: 10 µm. (D) Graph
of lamin intensities at the aspiration tip versus L/D. n = 5. Lamin intensities at aspiration tip were normalized to its
intensity throughout the rest of the nucleus. Bars, mean ± S.E.M; *p≤0.05, **p≤0.01, ***p≤0.001; two-way ANOVA
with Sidak’s multiple comparisons test. Curvature-intensity plots and micropipette aspiration experiments were
carried out by Travis Armiger and Prof. Kris Dahl, Carnegie Mellon University.
elongated nucleus forms a tight curve (i.e. high bending energy) at polar ends, as a result, these 
regions are more likely to be devoid of lamin B1. Consistent with our epifluorescence data, 
STORM images of elongated MEF nuclei also show the characteristic loss of lamin B1 at the polar 
ends (Figure 3.7C). To confirm the strain-dependent localization of the A- and B-type lamins, we 
A
C D
0
0.5
1
1.5
2
2.5
1 10
No
rm
al
iz
ed
 L
am
in
 In
te
ns
ity
Radius of curvature, R (µm)
LB1 LA/C
RI=0=1.8 µm R2 = 0.84
B
LB1 LA/C Merge
1 .2 1 .5 1 .7
0 .3
0 .6
0 .9
N o rm a liz e d  A s p ira t io n  L e n g th  (L /D )
N
o
rm
a
li
ze
d
 T
ip
 I
n
te
n
s
it
y
D s R e d -L A
G F P -L B 1
***
**
*
***
**
**
Pr
e-
as
p
L/
D 
= 
1.
2
L/
D 
= 
1.
7
DsRed-LAGFP-LB1 Merge+DNA BF
35 
used micropipette aspiration to induce and increase strain and visualize lamin intensity at the tip 
in the pipette, which is the region of highest strain (114) (Figure 3.6C). 
Micropipette aspiration experiments were carried out by Prof. Kris Dahl’s group at 
Carnegie Mellon University. At small aspiration lengths, normalized GFP-lamin B1 intensity is 
higher than normalized DsRed-lamin A intensity at the tip, which suggests that the stiff lamin A 
is resistant to deformation, as expected, compared to lamin B1. With increasing aspiration length, 
the normalized GFP-lamin B1 intensity significantly decreases at the tip, while normalized DsRed-
lamin A intensity remains relatively unchanged (Figure 3.6D). These findings are consistent with 
our imaging results and indicate that the network deformation of lamin B1 is influenced by strain 
at the pipette tip.  
Figure 3.7: Relationship between lamin intensity and bending energy. 
(A) Schematic representation of the relationship between curvature and its corresponding radius, R. A smaller R
defines a tighter curve, and R approaches infinity as the curve approaches a straight line. (B) Plot of normalized lamin
intensity versus effective bending energy for 30 points across 17 nuclei. Effective bending energy is proportional to
1/R2, where R is the radius of curvature. (C) Representative STORM images of a MEF at the nuclear equator showing
typical loss of lamin B1 at the polar ends of elongated nuclei. Scale bar: 2 µm.
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3.3.4  Bleb architecture is dependent upon lamin levels and localization
One physiological consequence of curvature-dependent localization of the A- and B-type 
lamins is evident in the structure of nuclear blebs, which are characteristic outward protrusions of 
the nuclear lamina. Blebs were initially reported as a consequence of nuclear lamin perturbations, 
most pronounced in lamin B1-null and HGPS cells (13, 103, 115). However, we observed that 
these blebs were also present in a fraction of wild type MEFs (19.1 ± 2.9%; Figure 3.8A and B) 
and untreated HeLa cells (12.2 ± 1.7%; Figure 3.9C). Plotting the ratio of bleb lamin fluorescence 
intensity to nuclear fluorescence intensity reveals that most blebs were devoid of lamin B1 (Figure 
3.8C). All nuclear blebs contained lamin A/C, while only a subset also contained lamin B1 (16.4 
± 2.5% in MEFs, 30.4 ± 3.0% in HeLa cells; Figure 3.8D). No blebs contained lamin B1 without 
lamin A/C also present. In the blebs that did contain lamin B1, the normalized fluorescence 
intensity of lamin B1 within the bleb was significantly lower than that of lamin A/C (Figure 3.8E), 
also suggesting that lamin B1 is depleted from blebs. 
To determine whether altering levels of the different lamin subtypes had any effect on bleb 
frequency, we then examined bleb formation in WT, Lmnb1-/-, and Lmna-/- MEFs (Figure 3.9A and 
B). Interestingly, we observed that while Lmna-/- MEFs were highly elongated and displayed 
ragged gaps at the polar ends, no blebs were present. In contrast, we observed a marked increase 
of bleb frequency in Lmnb1-/- MEFs. Lmnb1CS/CS MEFs also had more frequent blebbing nuclei, 
but not to the degree seen in Lmnb1-/- cells (Figure 3.8B). In agreement with the lamin-null MEF 
data, siRNA-induced reduction of lamin B1 increased bleb frequency while the reduction of lamin 
A decreased bleb frequency (Figure 3.9C). Therefore, a possible role of the outer lamin B1 
meshwork may be to prevent the A-type lamins underneath from expanding outward and forming 
nuclear envelope protrusions.  
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Figure 3.8: Lamin structure determines its roles in maintaining nuclear shape. 
(A) Confocal images of a WT MEF nucleus at the equatorial plane showing a typical nuclear envelope protrusion 
referred to as a bleb (arrow). Dashed line represents major axis. (B) Bleb frequency quantification among WT (n=178), 
Lmna-/- (n=178), Lamin B1-overexpressing (n=182), Lmnb1CS/CS (n=201), and Lmnb1-/- (n=201) MEF nuclei. (C) 
Histogram of bleb lamin intensity relative to nuclear body intensity in WT MEFs (n=214). Median ratios: 1.34 (LA/C), 
0.10 (LB1). (D) Frequencies of blebs that contain LA/C only vs. both LA/C + LB1 in primary MEFs (n=225) and 
HeLa cells (n=230). (E) Box-and-whisker plot of lamin fluorescence intensity ratios among blebs that contain both 
lamin A/C and lamin B1 in WT MEFs (n=24). (F) Nuclear bleb frequencies in HeLa cells treated with 0.1 nM (n=288) 
and 1 nM Cal-A (n=324), compared to DMSO-treated control (n=220). (G) Radius measurements of blebs containing 
only lamin A/C (n=158) vs. both A/C and B1 (n=31). (H) Radius measurements of blebs in WT (n=189) vs. Lmnb1-/- 
(n=87) MEFs. (I) Percentages of polar-localized blebs in WT (n=206) vs. Lmnb1-/- (n=87) MEFs. Bars, mean ± S.E.; 
*p≤0.05, **p≤0.01, ***p≤0.001; Chi-squared tests were used for B, F, and I; Wilcoxon matched-pairs signed rank 
test for E, and unpaired two-tailed t-test with Welch’s correction for G and H. 
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We hypothesized that rather than solely arising as a consequence of nuclear lamin 
perturbations, bleb formation may be a mechanism to redistribute tension on the lamina due to 
cytoskeletal forces exerted on the nucleus. To test this, HeLa cells were treated with 0.1 nM and 1 
nM Calyculin A (Cal-A), a potent PP1 and PP2A-C phosphatase inhibitor that induces contraction 
of the actin-myosin cytoskeleton (116). Intensifying intracellular stress to promote rapid nuclear 
compression may lead to an increase of bleb frequencies. Cal-A treatment indeed resulted in 
increased bleb frequencies over control cells in a dose-responsive manner (Figure 3.8F). The short 
treatment period (30 min) ensures that the differences in bleb frequencies are not due to nuclear 
reorganization induced by cell division. To confirm that the increased blebbing frequency was due 
to increased actin-myosin contractility and not due to due to off-target phosphorylation caused by 
Cal-A treatment, we used the cell-permeable myosin II inhibitor, blebbistatin, to reduce 
intracellular pressure by suppressing cell contraction. Blebbistatin treatment resulted in a dose-
dependent decrease of blebbing nuclei (Figure 3.9D). Notably, it eliminated Cal-A’s ability to 
induce blebbing, indicating that blebs likely arose due to increased intracellular pressure and not 
from non-specific effects of calyculin treatment.  
The architecture of the blebs allows us to test predictions that arise out of our model of the 
nuclear lamina, where the lamin B1 network is located towards the outside of lamin A/C, and the 
location of lamin B1 is curvature dependent. Based on our findings, we expect that that lamin B1 
is likely to be excluded from tightly curved regions of the nuclear envelope. Consistent with this 
prediction, we found that blebs containing lamin B1 are larger on average than lamin A/C-only 
blebs (Figure 3.8G). In addition, blebs that form in Lmnb1-/- MEFs are significantly larger than 
those in WT cells (Figure 3.8H). Further proof of the functional consequences of our model is seen 
in the location of blebs. If a role for lamin B1 is to stabilize the outward protrusion of the lamin 
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A/C network, we would expect to see a higher frequency of blebs in regions depleted of lamin B1. 
In agreement with our model, we observe that most blebs form at the major axis poles, where the 
radius of curvature is low resulting in a consequent depletion of lamin B1. However, in Lmnb1-/-  
 
Figure 3.9: Nuclear bleb rates are altered with lamin perturbations. 
(A) Epifluorescence microscopy images of WT, Lmnb1-/-, and Lmna-/- MEF nuclei stained against lamin B1 (green), 
lamin A/C (red), and DNA (blue). Arrows point to a nuclear envelope protrusion known as a bleb. Arrowheads point 
to areas of nuclear envelope ruptures with herniating chromatin. Scale bar: 10 μm. (B) Western blot of lamin proteins 
in Lmna-/-, Lmnb1-/-, and WT MEFs. (C) Quantification of nuclear bleb ratios among untreated control (n=386), siRNA 
scrambled (n=117), siRNA LMNA (n=206), and siRNA LMNB1 (n=159) treated HeLa cells. (D) Blebbistatin 
treatments of HeLa cells result in a dose-dependent reduction of blebbing nuclei frequencies compared to control. 1 
nM Cal-A co-treated with 50 µM blebbistatin results in the elimination of Cal-A-induced bleb formation. n = 250 - 
400 nuclei per group. (E) Western blot of WT vs. TRE-FLAG-LMNB1;Rosa-rtTA (TRE) transgenic MEFs that 
overexpress exogenous human FLAG-lamin B1 after the addition of 2 µg/mL doxycycline (+Dox) in vitro. Exogenous 
FLAG-lamin B1 (top band), endogenous lamin B1 (bottom band). M = protein size marker, with relevant band sizes 
labeled (kDa). (F) Nuclear bleb frequencies in WT vs. TRE MEFs ± Dox. n = 180 - 200 nuclei per group. Bars, ratio 
± S.E.; *p≤0.05, **p≤0.01, ***p≤0.001; chi-squared test. 
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MEFs where the constraining effects of lamin B1 are no longer present, blebs assume a more 
random distribution with a significant reduction in polar blebs (Figure 3.8I). 
To further test our hypothesis that lamin B1 inhibits the lamin A/C meshwork from 
protruding outward, we examined lamin B1-overexpressing MEFs (Figure 3.9E). Compared to 
WT and untreated cells, lamin B1-overexpressing cells had a significantly lower frequency of 
blebbing nuclei (Figure 3.8B and Figure 3.9F). By increasing lamin B1 expression, we could 
almost eliminate the formation of nuclear blebs. 
3.4 Discussion 
Super-resolution localization microscopy is a powerful imaging tool for simultaneous 
visualization of multiple molecular species at nanometer resolutions (110). Here, we have used 
STORM combined with quantitative image analysis to identify the spatial organization of A and 
B-type lamins. We find that the lamin B1 meshwork is closest to the INM and forms a less dense 
outer rim around the more tightly spaced lamin A/C meshwork facing the nucleoplasm, with a 
spatial separation of ~15-20 nm. Such precise localization of the two lamin species was achieved 
by several key technical attributes of our approach. First, it required chromatic aberration-free two-
color super-resolution imaging. A complete correction of chromatic aberration is often difficult to 
achieve, especially when the imaging target is farther away from the coverslip surface (as in our 
case of imaging equatorial plane of the nuclear periphery). To overcome this hurdle, we used the 
same reporter dye in the activator-reporter dye pairs in two-color STORM imaging to essentially 
eliminate any chromatic aberration. Second, by averaging spatial distribution around the nuclear 
periphery, we can quantify the separation of different lamin types at a higher precision than the 
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STORM imaging resolution of ~20 nm (102). Third, focusing on the equatorial plane maximizes 
the spatial resolution by imaging the projection of the cross-sectional profiles of the two lamin 
types across the nuclear periphery. 
Our biochemical data confirms the STORM imaging observations that lamin B1 is more 
closely associated with INM than lamin A/C and that this association is dependent upon the 
farnesylation of lamin B1. All lamins are initially farnesylated, but only B-type lamins retain their 
farnesyl group after prelamin A undergoes proteolytic cleavage at its C-terminus (1). This farnesyl 
tail can allow lamin B1 to tightly associate with the inner nuclear membrane, similar to the way 
Ras GTPases anchor to the cell membrane (117, 118), and provides a rationale for the retention of 
the farnesyl group by lamin B1. Interestingly, although the lamin B1 farnesyl mutant significantly 
altered the lamin B1 network structure, consistent with earlier reports using conventional 
fluorescence microscopy (23), our results also show that it did not alter lamin A/C distribution, 
suggesting that proper localization of lamin B1 is not required for the integrity of the lamin A/C 
network.  
While farnesylation of lamin B1’s CAAX domain is important for its peripheral 
localization, other post-translational modifications might also be maintaining nuclear envelope 
stability. For example, inhibition of Rce1-mediated endoproteolysis or Icmt-mediated 
carboxymethylation of lamin B1’s CAAX domain has been shown to result in compromised 
structural integrity of the lamina, namely with gaps in the lamin B1 meshwork through which 
chromatin herniations can be seen (111). Farnesylation of lamin B1 may be critical for its proper 
localization adjacent to the inner nuclear membrane, but it might not be the only factor. This can 
now be tested using the STORM imaging protocol we have described.  
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Taken together with their relative spatial organization at the nuclear periphery (the lamin 
B1 network overlaying the A-type lamin network), lamin B1 is also less likely to be present in 
tightly curved structures and is more responsive to bending energy. This implies that the nuclear 
lamina is composed of independent mechanical elements with distinct properties. Lamin A/C is 
known to contribute to the mechanical stiffness of the nucleus (103). Other STORM imaging data 
show that it forms a tighter meshwork that maintains the integrity of the nuclear lamina regardless 
of shape, as the lamin B1 meshwork has larger inter-filament spaces while being more bending 
energy responsive (data not included). This complement of stiff and strain-dependent deformable 
filament structures is not unique to the nuclear envelope. Similar multi-element mechanical 
complements are also found throughout the cytoskeleton (119).  
Although we are lacking data on lamin B2’s meshwork in this study, most of the nuclear 
envelope shape changes can be sufficiently modeled with the physical arrangement of lamin B1’s 
meshwork relative to that of A-type lamins, as well as their mechanical properties. Though 
knockdown of lamin B2 results in abnormal nucleolar morphology (120), Lmnb2-/- mouse 
fibroblasts do not have significant irregularities in their lamin meshwork (15), and do not exhibit 
higher frequencies of nuclear blebs than WT fibroblasts (121). It is therefore possible that lamin 
B2 might contribute very little to nuclear shape dynamics. 
Previous studies have shown that individual lamin A and C proteins preferentially 
homodimerize to form independent but similar mesh-like structures, with little detectable physical 
interaction with lamin B1 (122-124). Although we have not differentiated between the A- and C-
type lamins in our experiments, our model of the nuclear lamina is not incompatible with this 
finding, since it is not predicated upon A-type lamins together forming a single, heteromultimeric 
meshwork at the nuclear periphery. We show that A-type lamins form meshworks that 
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preferentially localize closer to the nucleoplasm, a future direction would be to determine if there 
are spatial localization differences between lamin A and lamin C networks just as we have 
observed between lamin A/C and lamin B1, using our sensitive dye pair STORM imaging protocol. 
Blebs are often considered to be related to pathological phenomena, especially in the 
context of laminopathies like HGPS (75) and Emery-Dreifuss Muscular Dystrophy (125), 
metastasizing cancers (126, 127), or as consequences of nuclear lamina perturbations such as  
lamin B1 silencing (13). However, we suggest that nuclear blebs are not necessarily pathological 
abnormalities but may be useful for the rapid nuclear morphology changes needed to respond to 
intracellular forces such as cytoskeletal contraction. This is supported by our results where a 
stimulated increase of intracellular forces using Cal-A resulted in significantly increased numbers 
of blebs. Our data is consistent with a recent report that blebs are also found in wild type cells and 
these are usually lacking lamin B1 (128). All blebs contain lamin A/C but only a minority also 
contain lamin B1. In these blebs, lamin B1 is significantly depleted. Together, these results suggest 
lamin A/C is a major driver of bleb formation. These findings are consistent with another report 
finding that depletion of all lamins leads to a complete absence of blebs (129). Our micropipette 
aspiration experiments showed that localization of GFP-lamin B1 and DsRed-lamin A/C along 
various aspiration lengths is dissimilar to what is observed in naturally occurring blebs. It is 
important to note that micropipette aspiration induces hyperphysiological strains - high force 
applied over short times - that allow us to induce energy-dependent deformations independently 
of cellular forces and visualize lamin network deformation at a rate faster than protein exchange 
or other biological processes. As such, these shorter time scales and higher forces probably 
contribute to the distribution of lamin A/C and lamin B1 appearing different than in blebs that 
occur under normal cellular forces of adherent cells. 
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We propose that most blebs lack lamin B1 for two main reasons: first, blebs form more 
readily in the absence of the outer stabilizing layer of lamin B1, and second, because of the 
curvature dependent localization, lamin B1 is less likely to be located within smaller structures 
like blebs once they are formed. Whether lamin B1 containing blebs develop from different cellular 
processes as the blebs containing only A-type lamins remains to be determined. Lamin B1 
degradation has been shown to be mediated by autophagy through nucleus-to-cytoplasmic 
transport of vesicles that deliver lamin B1 to the lysosome (95). It is possible that the lamin B1 
containing blebs represent nascent stages of such autophagic vesicles. 
We observed a marked difference in bleb orientation among WT and Lmnb1-/- MEF nuclei. 
Nearly 80% of blebs were positioned adjacent to the major axis poles in WT nuclei. With the 
complete lack of lamin B1, we observed a more random assortment of bleb positioning. In WT 
cells, the poles are the regions of high curvature and are consequently mostly devoid of lamin B1, 
while Lmnb1-/- cells are uniformly devoid of lamin B1. The blebbing pattern in these two cell types 
thus mirrors the depleted laminB1 localization and is consistent with our hypothesis that lamin B1 
plays a role in suppressing bleb formation in the nuclear envelope. While high curvature strain as 
a mechanism for preferentially-polar bleb formation as previously proposed still holds (128), our 
results suggest that this mechanism is also mediated by the absence of lamin B1 at these locations. 
In summary, we have identified a novel model for the spatial organization of the nuclear 
lamina based on two critical principles: 1) Lamin B1 forms a looser, outer meshwork facing the 
nuclear membrane while lamin A/C forms a tighter, inner meshwork facing the nucleoplasm, and 
2) Lamin B1’s meshwork is more curvature- and strain-responsive than lamin A/C’s meshwork, 
which affects its localization in tightly curved structures (Figure 3.10).  
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Figure 3.10: Schematic representation of lamin organization at the nuclear envelope. 
In animal cell nuclei, lamin B1’s meshwork (green) lies closest to the inner nuclear membrane, while lamin A/C’s 
meshwork (red) faces the nucleoplasm. (A) In circular or slightly elliptical nuclei, the B-type lamin meshwork is 
sufficient to contain the underlying A-type lamin meshwork. (B) Regions of high curvature in elongated nuclei can 
result in a dilation or loss of the lamin B1 meshwork. (C) Lamin A/C forms blebs through the gaps within the lamin 
B1 meshwork. Representative MEF nuclei displaying (D) circular, (E) elongated, and (F) blebbed morphologies as 
illustrated in the above models. Lamin B1 (green), lamin A/C (red), DNA (blue). 
 
This model reveals a role for lamin B1 in preventing the A-type lamin meshwork from 
protruding outward and can predict the disparate structural consequences of perturbing individual 
lamina components. However, this model does not explain the connection between lamin B1 and 
myelination. For that, aim 2 explores the role of lamin B1 in developing and mature 
oligodendrocytes. 
[Note: The data from this chapter has been published in: Nmezi B, Xu J, Fu R, Armiger 
TJ, Rodriguez-Bey G, Powell JS, Ma H, Sullivan M, Tu Y, Chen NY, Young SG, Stolz DB, Dahl 
KN, Liu Y, Padiath QS. Concentric organization of A- and B-type lamins predicts their distinct 
roles in the spatial organization and stability of the nuclear lamina. Proceedings of the National 
Academy of Sciences. 2019;116(10):4307.]  
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4.0 The Role of Lamin B1 in Mouse Oligodendrocyte Development and Proliferation 
4.1 Introduction 
The fact that ADLD pathophysiology exclusively consists of neurological symptoms 
despite a germline duplication of LMNB1, present in all cell types, suggests the possibility that 
lamin B1 has a special role in the nervous system. A routinely used method for discovering the 
roles of proteins in vivo is to generate knockout models of the gene in question in mice. Complete 
lamin B1-deficient mice are perinatal lethal (9), so tissue-specific conditional knockout models are 
required to study the role of lamin B1 in brain development. Previous research has found that lamin 
B1 in neurons is required for proper neuronal development and migration, as neuron-specific lamin 
B1-knockout mice exhibited impaired brain development and aberrant neuronal morphology (11, 
23). However, no changes in myelination, the hallmark of ADLD, have been described. Therefore, 
lamin B1 may also play an important role within other cells in the CNS – namely oligodendrocytes 
(OLs), the cells responsible for generating myelin. Previously published data showed that mouse 
OLs are very susceptible to overexpression of lamin B1 (80), leading to age-dependent ADLD-
like symptoms, so OL-specific Lmnb1 knockout mice should give us more insights into the roles 
of lamin B1 in myelination. To accomplish this, I utilized cre-lox recombination system to knock 
out Lmnb1 specifically in mouse OLs. The cre recombinase gene is under the transcriptional 
control of the OL-specific Cnp promoter, while the mouse Lmnb1 gene is flanked by loxP 
sequences (Lmnb1-flox). Double-transgenic mice hemizygous for Cnp-cre and homozygous for 
floxed Lmnb1 have Lmnb1 knocked out in OL lineage cells. 
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4.2 Materials and Methods 
4.2.1  Generation of conditional knockout transgenic mice 
Hemizygous Cnp-cre mice (Lappe-Siefke et al. (56)) were mated to homozygous Lmnb1fl/fl 
mice (Yang et al. (12), Jackson Laboratories #032558), on a C57BL/6J background. The resulting 
Cnp-Cre;Lmnb1fl/+ mice were again crossed to Lmnb1fl/fl (“Wt”) mice in order to get Cnp-
Cre;Lmnb1fl/fl (conditional knockout, “cKO”) mice. Further crosses were done using Cnp-
Cre;Lmnb1fl/fl x Lmnb1fl/fl in order to obtain 50% Wt and 50% cKO mice per litter. All cKO mice 
were hemizygous for the Cnp-Cre transgene.  Wt littermates were used as controls for their cKO 
counterparts, and mice of either sex were used in experiments. For tamoxifen injection of UBC-
Cre-ERT2 mice (Rusankina et al. (131), Jackson Laboratories #008085), tamoxifen (Sigma) was 
dissolved in corn oil (Sigma) at 20 mg/mL, and administered via IP injection at approximately 75 
mg/kg body weight every 24 hours for 5 consecutive days. All animals were housed in University 
of Pittsburgh animal facilities managed by the Division of Laboratory Animal Resources in 
accordance with Institutional Animal Care and Use Committee guidelines.  
4.2.2  Mouse genotyping 
Ear punches were used to genotype mice 20 days and older. For mice under 20 days of age, 
1-2 mm of tail snips were used. Ear punches and tail snips were digested in DirectPCR Tail Lysis 
Buffer supplemented with 200 µg/mL proteinase K (Viagen) overnight at 55°C. Samples were 
centrifuged at 12,000xg for 1 minute and 2 µL of supernatant was used for genotyping PCR. 
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Genomic DNA used in PCR was diluted to 50 ng/uL working concentration, and 100 ng DNA was 
used per reaction. Genotyping primer sequences are listed in Appendix B. 
4.2.3  Open field activity monitoring test 
Activity monitoring tests were performed in the Rodent Behavior Analysis Core at the 
University of Pittsburgh. Tests were performed in controlled conditions during the day phase of 
the day/night cycle. 5 Wt and 5 cKO mice at 5 months old were used for testing. Mice were 
individually placed into an open-field apparatus (43 x 43 x 30 cm; Med Associates) and allowed 
to freely explore for 30 minutes. Horizontal and vertical movements were monitored with infrared 
light beams and detectors. Beam interruptions were analyzed with custom software (Med 
Associates) that measure ambulation, velocity, distance traveled, and rearing. 
4.2.4  Tissue dissection and processing 
For genomic DNA, RNA, and protein isolation, mice were euthanized with CO2 inhalation 
and the brain and cervical spinal cord were dissected over cold 1x PBS. Brains were cut in half, 
separating the left/right hemispheres, then further separated into forebrain, brainstem, and 
cerebellum. Cervical spinal cords were cut to separate proximal/distal halves. All samples were 
then snap frozen in liquid nitrogen and stored at -80°C until ready for processing. CKO samples 
and their corresponding Wt controls were always taken on the same day. For cell proliferation, 
animals at postnatal day 5 were injected with 100 μg/kg-bodyweight 5-ethynyl-2´-deoxyuridine in 
PBS, three times with 4 hours between each injection, and perfused 24 hours after time of first 
injection. For immunostaining, mice were anesthetized with intraperitoneal injection of 2.5% 
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2,2,2-tribromoethanol (Sigma), then transcardial perfusion was performed with ice-cold 1x PBS 
followed by ice-cold 4% formaldehyde in PBS. Brain and spinal cord were extracted then post-
fixed overnight with 4% formaldehyde in PBS, followed by cryoprotection with 30% sucrose in 
PBS at 4°C. Samples were embedded in OCT (Fisher) over dry ice, and 10 µm cryosections were 
taken for immunostaining on Superfrost Plus slides (Fisher). For EM analysis, mice were 
transcardially perfused with ice-cold 1x PBS followed by 4% formaldehyde and 2.5% 
glutaraldehyde in PBS. For TEM analysis, specimens were processed at the University of 
Pittsburgh Center for Biologic Imaging. The specimens were rinsed in PBS, post-fixed in 1% 
osmium tetroxide (Electron Microscopy Sciences) with 1% potassium ferricyanide (Fisher), 
dehydrated through a graded series of ethanol (30% - 100%, Fisher) and propylene oxide (Electron 
Microscopy Sciences), and embedded in Poly/Bed® 812 (Luft formulations) and 
Dimethylaminomethyl (Polysciences).  Semi-thin (300 nm) sections were cut on a Leica Reichart 
Ultracut (Leica Microsystems), stained with 0.5% Toluidine Blue in 1% sodium borate (Fisher) 
and examined under the light microscope.  Ultrathin sections (65 nm) were stained with 2% uranyl 
acetate (Electron Microscopy Sciences) and Reynold’s lead citrate (Fisher) and examined on JEOL 
1011 transmission electron microscope (JEOL, grant #1S10RR019003-01 NIH for Simon 
Watkins) with a side mount AMT 2k digital camera (Advanced Microscopy Techniques). 
4.2.5  Genomic DNA extraction 
Frozen mouse brain samples were crushed in a ceramic mortar and pestle over dry ice and 
~100 mg were incubated in cell lysis solution (Qiagen) with proteinase K (Viagen) overnight at 
55°C. Genomic DNA extraction was carried out using the Gentra Puregene kit (Qiagen) according 
to the manufacturer’s instructions. 
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4.2.6  RNA extraction and real-time PCR 
Samples were homogenized in TRIzol (Invitrogen) using a Dounce homogenizer (Kimble), 
and extracted according to the manufacturer’s protocol. cDNA was synthesized from 1 μg RNA 
using qScript cDNA Synthesis Kit (Quanta Bio). Real-time PCR was performed using PerfeCTa 
SYBR Green SuperMix with ROX (Quanta Bio) on an ABI QuantStudio 12K Flex (Applied 
Biosystems). Data were analyzed using the ΔΔCT method (132), using mouse β-actin (Actb) as an 
endogenous control. Real-time PCR primer sequences are listed in Appendix B. 
4.2.7  Western blotting 
Protein lysates from brain and spinal cord were obtained by homogenizing them in T-PER 
supplemented with 1x protease inhibitor cocktail (Thermo Scientific). Protein concentration was 
measures by BCA protein assay kit (Thermo Scientific). PAGE was performed with up to 50 μg 
total protein in each well of a 10% polyacrylamide gel (Bio-Rad), and proteins were transferred to 
nitrocellulose membranes (Bio-Rad), followed by blocking with 4% nonfat milk in TBS or 1x 
Odyssey blocking buffer (LI-COR Biosciences) for 1 hour at room temperature. Membranes were 
incubated with primary antibodies diluted in 5% nonfat milk in TBS or 1x Odyssey blocking buffer 
with 0.1% Tween-20 (Fisher) overnight at 4°C with gentle shaking. Primary antibodies used and 
their dilutions are listed in Appendix A. The next morning, membranes were washed three times 
for 10 minutes each with TBS-T (TBS + 0.1% Tween 20), and incubated with goat anti-mouse 
680LT (LI-COR #926-68020) and donkey anti-rabbit 800CW (LI-COR #926-32213) secondary 
antibodies diluted 1:10000 in Odyssey blocking buffer + 0.1% Tween 20 for 1 hour at room 
temperature in the dark. After three 10-minute washes in TBS-T, membranes were scanned, 
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imaged, and quantified using the LI-COR Odyssey CLx infrared scanner and Image Studio 
software (LI-COR Biosciences). 
4.2.8  Immunofluorescence staining 
Sections on slides were circled with a PAP pen to form a hydrophobic barrier, and were 
blocked using 5% normal donkey serum (Jackson ImmunoResearch) + 0.3% Triton X-100 (Sigma) 
in PBS for 1 hour at room temperature. Primary antibodies were diluted in PBS + 1% BSA (Sigma) 
+ 0.3% Triton X-100 and incubated with the cells overnight at 4°C. Primary antibodies used and 
their dilutions are listed in Appendix A. The next morning, primary antibody dilutions were 
discarded and slides were washed with PBS three times for 5 minutes each at room temperature. 
FITC conjugated donkey anti-rabbit (Jackson ImmunoResearch #711-095-152) and Cy3 
conjugated donkey anti-mouse (Jackson ImmunoResearch #715-165-150) secondary antibodies 
were each diluted 1:350 in PBS + 1% BSA, and incubated with the sections for 1 hour at room 
temperature in the dark. Slides were washed three times for 5 minutes each in PBS, then mounted 
with 24 x 50 mm glass coverslips (Corning) and Vectashield antifade mounting medium with 
DAPI (Vector Laboratories). 
4.2.9  Imaging and quantification 
The following imaging was done in the Padiath lab (Department of Human Genetics): 
Wide-field microscopy images were acquired of immunofluorescently-labeled tissues on a Leica 
DM5000B upright microscope and Leica DFC310 FX digital camera (Leica). Five to seven non-
overlapping fields across corpora callosa (medial to lateral) were quantified per brain section, with 
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four 10 μm sections from each mouse representing approximately 0.5 mm from the bregma (rostral 
to caudal) using 20x and 40x objectives. Counts were done via imageJ (FIJI) using regular counting 
analysis, counting cells per corpus callosum field. Results were graphed as the average of counts 
per field per mouse. 
4.2.10  Statistical analysis 
Two-sided t-tests were used to calculate statistical significance between two groups. The 
following convention for representing p values was followed: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
A p-value ≤ 0.05 was considered statistically significant. All error bars represent standard error 
unless otherwise specified. Data were graphed and analyzed in Microsoft Excel 2016 and 
GraphPad Prism 7. 
4.3  Results 
4.3.1  Lmnb1 is partially deleted in conditional knockout mice 
To study the effect that deletion of Lmnb1 has on the development of OLs, I used 
previously generated transgenic mice expressing Cre recombinase under the control of the Cnp 
promoter and mated them into lines with homozygous floxed Lmnb1. Cnp1 codes for 2',3'-Cyclic-
nucleotide 3'-phosphodiesterase (Cnpase), a myelin-associated enzyme (133) whose promoter 
sequence has been previously used to target gene expression in mouse OLs (134). To confirm that 
Lmnb1 is being deleted in conditional knockout (cKO) mice, I designed primers surrounding the 
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loxP sequences flanking exon 2 in Lmnb1-flox mice to test specificity and effectiveness of 
recombination (Figure 4.1A). Amplification of floxed Lmnb1 results in a 2.1 kb fragment, 
compared to Wt (non-floxed) Lmnb1’s 1.35 kb fragment. The removal of exon 2 by cre 
recombinase results in an 850 bp PCR product. The PCR shows the deleted Lmnb1 in band in cKO 
mice is specific to DNA extracted from their CNS and not from ear punches, thanks to the 
specificity of the Cnp promoter (Figure 4.1B). As a positive PCR control for Lmnb1 deletion, I 
have used genomic DNA from Lmnb1-flox mice also carrying UBC-Cre-ERT2 injected with 
tamoxifen (131). Note that there is still a faint PCR product corresponding to uncut floxed Lmnb1 
in the cKO brain. Since not all cells in the brain are of OL lineage, a population would not express 
the Cnp-cre transgene and would therefore show the uncut floxed Lmnb1 PCR product. The 
smaller PCR band corresponding to the deleted Lmnb1 gene is preferentially amplified in PCR, 
therefore it does not accurately represent the ratio of recombined to un-recombined DNA. 
 
Figure 4.1: Characterization of Lmnb1 cKO mouse knockouts. 
(A) Mechanism of action (not to scale). Cre recombinase excises Lmnb1 exon 2, which is flanked by loxP sequences. 
“For” and “Rev” designate primers used to confirm genomic DNA deletion of exon 2 after recombination. (B) PCR 
confirmation of brain-specific excision. Genomic DNA from cerebellum (CB) and ear punch of a Cnp-Cre;Lmnb1fl/fl 
mouse was PCR amplified along with ear punch from a UBC-Cre;Lmnb1fl/fl and CB samples from one Lmnb1fl/fl and 
two Wt mice. Expected sizes: Lmnb1-flox = 2.1 kb, Lmnb1-Wt = 1.35 kb, Lmnb1-Δ = 840 bp. (C) Lmnb1 mRNA and 
(D) protein expression is mildly reduced in cKO whole forebrain (FB) compared to Wt samples. Graphs are average 
± SEM, n = 3. 
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Total mRNA and protein analyses of mouse forebrain show a small but statistically 
insignificant reduction of lamin B1 (Figure 4.1C and D). This is because the brain is composed of 
a diverse population of cells, only a small portion of which are of OL lineage. Therefore, not all 
cells within the forebrain will express the Cnp-Cre transgene, and any reductions in OLs may be 
masked by lamin B1 expression from various other cell types. Since it is challenging to find 
measurable expression differences of lamin B1 protein and mRNA from total brain tissue, 
immunofluorescence microscopy was used to analyze lamin B1 expression changes within OL 
lineage cells of the corpus callosum. We focused on the corpus callosum as it is a well-defined 
white matter (i.e. myelinated) region. Analysis of Olig2, a transcription factor that marks all OL-
lineage cells, and lamin B1 co-staining in P6, P15, and P30 mouse corpora callosa (Figure 4.2A-
D) show a significant decrease of Olig2 and lamin B1 double-positive cells in cKO versus Wt 
sections  at P15 and P30, but not at P6 (Figure 4.2E). The Cnp-Cre transgene is not activated early 
enough (by P6) to eliminate Lmnb1 expression completely from progenitor cells (134). Since lamin 
B1 is a long-lived protein (135), the lamin B1 that we still see in OLs may be previously-generated 
protein that has yet to be degraded.  
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Figure 4.2: Lamin B1 is reduced in cKO brains at P15 and P30, but not P6. 
Representative images of (A) P15 Wt, (B) P6 cKO, (C) P15 cKO, and (D) P30 cKO corpus callosum stained for Olig2 
and lamin B1. Arrows point to examples of Olig2+ cells that are also lamin B1+. (E) Counts of Olig2+ cells that also 
contain lamin B1 show that cKO mice have a significant decrease of lamin B1 in oligodendrocytes at P15 and P30 but 
not at P6. Graphs are average ± SEM, n = 3, ** = p < 0.01. 
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4.3.2  No differences in activity or brain sizes between cKO and Wt mice 
At all ages, cKO mice were physically indistinguishable from their Wt counterparts. Open-
field activity tests in adult mice show no differences between Wt and cKO mice in all measured 
characteristics (Figure 4.3A). Whole brains from cKO mice also did not appear grossly altered, 
being the same size as brains from Wt mice at all ages, from 15 days old to 1 year (Figure 4.3B).  
 
Figure 4.3: There are no discernible physical differences between Wt and cKO mice. 
(A) Quantification of 30 minute open field activity monitoring of 5 month old mice. n = 6. (B) Size comparisons of 
perfused and formaldehyde-fixed brains from P15 (left) and 12 month old (right) Wt and cKO mice, showing no 
differences in size or development. 
 
A
P15
Wt cKO
12 mo
Wt cKO
B
0
200
400
600
800
1000
1200
1400
Average
Velocity
(mm/s)
Ambulatory
Distance
(cm)
Ambulatory
Time (s)
Resting Time
(s)
Vertical
Time (s)
Open field activity measurement
WT
cKO
 57 
4.3.3  Myelin gene expression is unchanged in cKO mice 
 
Figure 4.4: Reduction of Lmnb1 in mouse oligodendrocytes. 
Lmnb1 reductions in mouse mature oligodendrocytes does not result in large myelin protein expression expression 
changes in mouse forebrain. Cnpase is reduced by 50% in all cKO animals due to the knock-in of Cre transgene. 
Graphs are fold relative Wt control ± SEM. n = 3 biological replicates, * = p<0.05, ** = p<0.01, *** = p<0.001. 
 
Real-time PCR analysis of myelin genes Plp, Mbp, Mog, and Mag in mouse forebrain 
samples show mostly no significant differences in Wt versus cKO at all time points (Figure 4.4A). 
P30 cKO mRNA had slightly higher expression of Mbp and Mog that were statistically significant, 
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PLP and MBP expression within Wt versus cKO samples at all time points (Figure 4.4B). 
However, we do see reductions of MOG and MAG protein in cKO mice. It is unclear if these 
reductions are physiologically relevant, considering they do not affect mouse activity or survival 
into adulthood. In all cKO mice at all timepoints, Cnpase protein and mRNA expression is reduced 
by approximately half. This is not due to the knockout of Lmnb1, but because the insert of the 
transgenic Cre recombinase gene into the mouse Cnp locus via knock-in thus inactivating one copy 
of the gene (56). Previous research using these mice as a heterozygous knockout model of Cnpase 
did not find differences in survival or behavior compared to Wt mice up to 1 year of age (56, 136). 
4.3.4  Alterations in numbers of OL lineage cells in cKO mice  
Although we did not observe any overt alterations in the levels of myelin proteins, as lamin 
B1 is known to play a role in cellular proliferation and differentiation, we sought to determine 
whether loss of lamin B1 can impact the number and maturity of OL lineage cells in the corpus 
callosum using immunohistochemistry (IHC). To identify OLs in different stages of maturation, 
we used markers that have been previously shown to be specific for each stage. The OL-specific 
transcription factor Olig2 is present in all OL lineages irrespective of their maturation stage. 
PDGFRα is expressed by oligodendrocyte progenitor cells (OPCs) while CC1 is expressed by 
mature OLs (137-140). PDGFRα+Olig2 double labeling thus marks OPCs while CC1+Olig2 
labeling marks mature OLs.  
PDGFRα+Olig2 staining did not show significant differences between Wt and cKO mouse 
brains at P15 (Figure 4.5A and B), but CC1+Olig2 staining showed significant decreases at both 
P15 and P30 (Figure 4.5C and D). This would suggest that OPCs lacking lamin B1 have defects 
in their ability to differentiate into mature OLs. 
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Figure 4.5: cKO mice OPCs have differentiation defects. 
(A) Wt vs. cKO P15 brain sections stained against Olig2 (red) and PDGFRα (green). Arrows point to examples of 
cells that are positive for both. (B) Quantification of PDGFRα+Olig2 double-positive cell counts in mouse corpus 
callosum at P15 and P30. There are no differences between Wt and cKO mice. (C) Wt vs. cKO P15 brain sections 
stained against Olig2 (red) and CC1 (green). Arrows point to cells positive for both. (D) Quantification of CC1+Olig2 
double-positive cell counts in mouse corpus callosum at P15 and P30, showing a reduction of CC1+ cells in cKO 
brains. Graphs are average ± SEM. n = 3 biological replicates, ** = p<0.01, *** = p<0.001. 
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see no lamin B1 in mature OLs, it is possible that small population of OPCs that escape the excision 
of the lamin B1 locus would preferentially differentiate into mature OLs and therefore supplant 
the OLs lacking lamin B1. The fact that we can observe mature OLs without lamin B1 would 
suggest that OPCs have maturation difficulties without lamin B1, but they are also able to survive 
once matured. This is consistent with previous data demonstrating that lamin B1 levels are 
significantly reduced in mature OLs (141).  
 
Figure 4.6: There are fewer mature oligodendrocytes with lamin B1 in cKO mouse brains. 
Immunofluorescent staining of (A) Wt and (B) cKO mice against lamin B1 (green) and CC1 (red) in the medial corpus 
callosum. Arrows point to CC1+ cells that are negative for lamin B1. (C) Counts of CC1+ cells per field show there 
are fewer mature oligodendrocytes in cKO brains at P15, with a large difference at P30. (D) counts of CC1+lamin B1 
double-positive cells per field show there are fewer mature oligodendrocytes with lamin B1 in cKO brains. Graphs 
are average ± SEM. n = 3 biological replicates, * = p<0.05, ** = p<0.01, *** = p<0.001. 
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To determine whether there were proliferation defects in OL lineages in the cKO mice, we 
measured 5-ethynyl-2’-deoxyuridine (EdU) staining, a nuclear marker for proliferating cells. Mice 
were injected with thymidine analog EdU at P6 and P15, and Olig2+EdU cells in the corpus 
callosum were stained and counted. P6 brains had a higher proportion of replicating OLs than P15 
brains in general, but no significant differences were seen between Wt and cKO brains (Figure 
4.7A). However, EdU is only incorporated into cells at the S-phase of the mitotic process, 
consequently underestimating the number of dividing cells in the CNS (142). Other proliferation 
markers such as Ki-67 should be used to investigate OL proliferation in future studies. To confirm 
that the reduction in the number of mature OLs in the cKO mice was not due to apoptosis, we 
carried out staining for activated caspase 3, a cytoplasmic marker for apoptotic cells, across all 
time points (Figure 4.7B). No Olig2+ cells that were also positive for activated caspase 3 were 
observed in corpora callosa of Wt or cKO mice.  
 
Figure 4.7: It is unclear if cKO oligodendrocytes have proliferation defects. 
(A) Proportion of Olig2+ cells that are EdU+ 24 hours after IP injection of EdU is very small in both Wt  and cKO 
mice. There are no significant differences between Wt and cKO mice. Graphs are average ± SEM, n = 3. (B) 
Representative immunofluorescence staining of Olig2 (red, arrowheads) and activated caspase 3 (green, arrow) in the 
caudate putamen of a P15 mouse. No Olig2+ cells had activated caspase 3 staining at P15, P30, or 3 months in the 
corpus callosum or other imaged sections of the brain. 
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4.4  Discussion 
Our results indicate that the loss of lamin B1 in OL lineages leads to a reduction in the 
number of mature OLs. Given that we did not observe an alteration in OPC numbers in the cKO 
mice, this would indicate that lamin B1 lacking OPCs are defective in their subsequent ability to 
differentiate into mature OLs.  
We did not observe any obvious functional defects in the expression of myelin proteins nor 
in the gross morphology of the brain or of the corpus callosum, the major white matter tract that 
we have studied. Expression of Plp, Mbp, Mog, Mag or their protein products are minimally altered 
in the forebrains of cKO mice. At 5 months, cKO mice do not exhibit activity changes. Mature 
cKO mice are also physically indistinguishable from their Wt littermates up to at least one year of 
age. While this could suggest that lamin B1-lacking OLs are functionally normal, this explanation 
must be qualified by a few caveats. We observed a significant number of mature OLs (~ 50%) that 
did exhibit lamin B1 expression. We reasoned that these represented the progeny of a small 
population of OPCs that escaped excision by the cre recombinase but that preferentially matured 
into OLs. In addition, Lamin B1 is also known to be an extremely long-lived protein. Thus, even 
if the lamin B1 locus has been excised in the late OPC and early OL stages, the residual lamin B1 
from OPCs could still remain and account for the lamin B1 positive OLs we have observed. 
The relatively normal myelination profile could therefore be due to these populations of 
OLs that still retain lamin B1 and would mask any functional defect due to the lamin B1 lacking 
OLs. The Cnp promoter is thought to express in the late OPC stage and become strongest in mature 
OLs. This is consistent with our observation that Lmnb1 is not knocked out at P6 and exhibits a 
maximal reduction in expression only at later time points (53). While our results point to a defect 
in the differentiation from OPCs to OLs as the cause of the reduction in the number of mature OLs 
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in the cKO mice, it would be premature to conclude that it does not have any effect on the 
proliferation of OPCs. It is important to remember that mature OLs lose their ability to replicate, 
and that proliferation only occurs in OPCs. Thus, we would ideally want to ablate lamin B1 in the 
early OPC stage using a different promoter such as Olig2 (143). Experiments using Olig2-Cre 
mice crossed to lamin B1 floxed mice are now underway, which would allow us to more clearly 
define the role of lamin B1 in OPCs and determine whether the reduction in mature OLs we 
observe is also not due to a replication defect. We also aim to measure ultrastructural changes to 
myelination in young and old mice. 
Considering that the consequences of excess lamin B1 protein in mature OLs lead to severe 
demyelination (80, 144), lamin B1 expression is tightly regulated in mature OLs for their proper 
function (145). Mature OLs may fare well with Lmnb1 knockout because its expression is already 
meant to be downregulated at that stage. Future studies into lamin B1 regulation in OLs and white 
matter has interesting implications with respect to demyelinating diseases such as ADLD: there 
may be OL-specific regulatory mechanisms of lamin B1 found in humans. Aim 3 further explores 
this possibility in detail. 
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5.0 Genomic Rearrangements Involving LMNB1 and ADLD Pathogenesis 
5.1 Introduction 
In my second aim, I established that a knockout of lamin B1 in mouse OLs in vivo does not 
result in obvious morphological or behavioral deficiencies, so mature OLs may be able to function 
normally with minimal lamin B1. On the other hand, OLs are very susceptible to increased lamin 
B1 levels, as its overexpression leads to severe ADLD-like symptoms in mice (80). For this reason, 
OLs may employ unique mechanisms for reducing lamin B1 expression once matured. 
Canonically, head-to-tail tandem genomic duplications of LMNB1 cause ADLD (77). It is 
thought that an extra copy of LMNB1 is sufficient to cause its overexpression thus leading to the 
classic ADLD phenotype. As it turns out, this is not always the case. Previous research has 
described a family with ADLD that did not have duplication of LMNB1 (88). Instead, this family 
has a large genomic deletion upstream of LMNB1. It is currently hypothesized that lamin B1 
overexpression in this case is caused by the deletion of a boundary that separates one topologically 
associating domain (TAD) from another. This deletion merges LMNB1 and upstream enhancers 
into the same TAD, presumably leading to the enhancers inducing lamin B1 overexpression. 
However, this mechanism does not sufficiently explain other CNVs in the pathogenesis of ADLD. 
For example, I have found that not all LMNB1 duplications lead to ADLD. In this chapter, I will 
describe families that have non-recurrent genomic duplications surrounding LMNB1 but lack 
demyelinating disorders. Understanding how CNVs surrounding LMNB1 lead to disease could be 
the key to understanding how LMNB1 is regulated within OLs and white matter. 
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Here, I have used array-based comparative genomic hybridization (aCGH) on DNA from 
patients with ADLD or autonomic dysfunction to correlate their copy number variants in 5q23.2 
to their clinical outcomes. I propose a novel OL-specific cis-regulatory element that silences 
LMNB1 expression in white matter. The existence of such an element would offer a comprehensive 
model linking copy number variants surrounding LMNB1 with ADLD pathogenesis. 
5.2 Materials and Methods 
5.2.1  Collection of clinical data, DNA isolation, and array CGH 
All clinical evaluations took place at their respective institutions, under the guidelines of 
their institutional review boards. All participants provided written informed consent. Genomic 
DNA from whole blood, saliva, primary fibroblasts and brain tissue was isolated using the Gentra 
Puregene kit (Qiagen) according to the manufacturer’s instructions. aCGH was performed at the 
University of Pittsburgh on genomic DNA from clinical samples, hybridized a custom 8x15K HD-
CGH microarray, scanned in a G2565CA microarray scanner, and analyzed using Agilent CGH 
Analytics software (Agilent Technologies) according to the manufacturer’s instructions. Human 
genome assembly GRCh37/hg19 was used for all genome coordinates. PCR primers were designed 
to specifically amplify the tandem duplication junctions for each family using Longamp Taq 
Polymerase (New England Biolabs), then Sanger sequenced (Eurofins Genomics) after treatment 
with ExoSAP-IT reagent (Applied Biosystems). 
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5.2.2  Primary fibroblast isolation and cell culture 
Patient and control skin biopsies were minced to smaller than 1.0 mm3 pieces then 
incubated with 0.05% Trypsin-EDTA (Sigma) for 3 hours at 37°C with gentle mixing. Pieces were 
then plated on a 10-cm tissue culture dish (ThermoFisher) with a minimal amount of DMEM 
complete (high glucose DMEM (Corning) supplemented with 10% FBS (Fisher), 2mM L-
glutamine (Millipore), and 1% penicillin-streptomycin (Hyclone)) until they adhered to the culture 
dish. Primary fibroblasts were trypsinized and re-plated into new dishes as they exited the explant. 
5.2.3  RNA isolation and real-time PCR 
RNA was isolated from cells and brain tissue using TRIzol reagent (Invitrogen) following 
the manufacturer’s instructions. cDNA was synthesized from 1 μg of RNA using qScript cDNA 
Synthesis Kit (Quanta Bio). Real-time PCR was performed using PerfeCTa SYBR Green 
SuperMix with ROX (Quanta Bio) on an ABI QuantStudio 12K Flex (Applied Biosystems). Data 
were analyzed using the ΔΔCT method using human β-actin (ACTB) as an endogenous control. 
Primer efficiencies were validated using 6-fold serial dilutions of cDNA. Real-time PCR primer 
sequences are listed in Appendix B. 
5.2.4  SNP height analysis 
Primers were designed to amplify the 3’ untranslated region (UTR) of the human LMNB1 
gene encompassing SNPs rs1051643 and rs1051644. Primer sequences are listed in Appendix B. 
PCR products were treated with ExoSAP-IT reagent (Applied Biosystems) then Sanger sequenced 
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(Eurofins Genomics). Sequences and electropherograms were analyzed using Sequencher v. 5.4 
software (Gene Codes). 
5.3 Results 
5.3.1  Genomic deletions upstream of LMNB1 lead to ADLD 
Patients from three unrelated families (DEL1, DEL2, and DEL3) had ADLD, but were 
negative for mutations in known disease-causing genes including duplications of LMNB1. A 
custom aCGH assay was used to map copy number variants surrounding LMNB1 on 5q23.2, 
revealing large heterozygous deletions from ~250 kb to ~670 kb extending to within ~4.8 kb to 88 
kb upstream of LMNB1 (Figure 5.1). Analysis of the deletion boundaries revealed that all 
boundaries lie within highly repetitive elements such as Alu repeats and long interspersed 
nucleotide elements (LINEs) (Table 3.1). It is likely that genomic deletions occur through non-
allelic homologous recombination or microhomology-mediated end joining (146). Deletion events 
were also clearly non-recurrent: each family has a unique deletion upstream of LMNB1. 
 
Table 5.1: Details of ADLD deletion families 
Family ID Centromeric junction 
(chr5) 
Telomeric  
junction 
(chr5) 
Deletion 
size 
(kb) 
Centromeric 
repeat Telomeric repeat Microhomology at junctions 
DEL1 125857895 126108379 250 Alujr AluSp None 
DEL2 125352465 126024979 673 10bp LINE homology LINE (LIMC5) None 
DEL3 125492412 126101296 609 AluSg7 AluSP 26 bp 
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Using aCGH data, I identified the “critical deletion region” (“Del Crit”) from the overlap 
of all identified deletion coordinates. Del Crit extends from chr5:125857895-126024979 (Figure 
5.1) and encompasses three genes: ALDH7A1, PHAX, and TEX43; as well as a boundary between 
two topologically associating domains (TADs) previously determined by chromosome 
conformation capture (86, 147), separating LMNB1 from previously-identified enhancer elements 
upstream of LMNB1 (88). It is possible that the deletion of this TAD boundary would result in 
aberrant interactions between LMNB1 and these upstream enhancers. While this remains plausible, 
another mechanism of action may be involved, which will be explored next.  
 
Figure 5.1: Schematic representation of upstream deletions that lead to ADLD. 
Blue bars represent deleted regions. DEL1, DEL2, and DEL3 are unrelated families with ADLD. “Enh” refers to a 
putative forebrain-specific enhancer element [83]. The minimal overlapping region of all deletions is defined as the 
critical deletion region (“Del Crit”) which includes PHAX, ALDH7A1, TEX43 (not pictured), and a topologically 
associated domain boundary. 
5.3.2  Large genomic duplications surrounding LMNB1 do not cause ADLD 
Patients from three unrelated families (K9, K11, and Port) were found to have mild 
autonomic disorders with an autosomal dominant inheritance pattern. Custom aCGH analysis in 
5q23.2 found a heterozygous duplication involving the LMNB1 gene, but intriguingly, they showed 
Del Crit
DEL1 (250kb)
DEL2 (673kb)
DEL3 (609kb)
GRAMD3 PHAX LMNB1 MARCH3
TAD1 TAD2
TDB
chr5 125,000,000 126,500,000ALDH7A1Enh
 69 
no symptoms of ADLD and Magnetic Resonance Imaging (MRI) revealed no signs of 
demyelination. This was true even in patients >60 years of age, by which time patients with ADLD 
show significant MRI alterations, are profoundly debilitated by limb weakness, and in some cases 
paralysis (148, 149). Their genomic duplications include not only LMNB1, but a significant portion 
of the upstream sequences as well. Duplication sizes range from ~466 kb to over 4.3 Mb (Figure 
5.2A), much larger than the typical duplication sizes found in ADLD patients: ~150 kb to ~200 kb 
(81). Sequencing analysis revealed that patients have simple tandem duplications with repetitive 
elements surrounding most of the duplication breakpoints (Table 3.2), therefore these duplications 
are likely caused by replication-based mechanisms such as microhomology-mediated break-
induced replication (MMBIR) (83).  
 
Table 5.2: Details of large duplication families 
Family ID Centromeric junction 
(chr5) 
Telomeric 
junction 
(chr5) 
Duplication 
size (kb) Centromeric repeat Telomeric repeat Microhomology at junctions 
P1 125253821 126285172 1,031,351 LTR: HERVP71A None None 
K9 125847699 126314321 466,623 SINE: AluSx LTR: Charlie4z AG 
K11 121812949 126178948 4,366,000 LTR: HERVH LTR: HERVH 49 bp 
BR1 
Ref. [81] 125699519 126174517 474,998 LINE: L1MB7 None Complex 
 
However, not all families with large duplications are spared from demyelination. 
Previously identified family “BR1” (81) has a ~475 kb heterozygous duplication surrounding 
LMNB1, and affected members have very severe ADLD symptoms with much earlier ages of onset 
(their twenties instead of forties to fifties). This duplication is also unique in its complexity: instead 
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of having a simple tandem duplication like other families with ADLD, BR1’s duplicated copy is 
inverted and inserted just upstream of LMNB1 (Figure 5.2B).  
 
Figure 5.2: Schematic representation of large genomic duplications involving LMNB1. 
(A) Green bars represent duplicated regions. K11, Port, and K9 are families identified in this study that have LMNB1 
duplications but no ADLD. BR1 is a previously-identified family (Giorgio et al. 2013, [81]) with a severe form of 
ADLD. The large duplication critical region “LD Crit,” the overlap of all known large duplications, defines the 
minimal duplicated region that includes LMNB1 but does not lead to ADLD. (B) Schematic representation of typical 
CNVs surrounding LMNB1 and their ADLD outcomes. The duplication within BR1 family is inverted and inserted 5’ 
of LMNB1’s transcription start site. 
 
Our data so far suggest that the canonical model of ADLD etiology – a simple tandem 
duplication of LMNB1 – is no longer sufficient to explain the mechanisms of LMNB1 
overexpression. Patients lacking LMNB1 duplications may still develop ADLD, while some with 
duplicated LMNB1 do not. I define the “critical large duplication region” (“LD Crit”) as the 
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minimal overlapping region of all known LMNB1 duplications without ADLD (therefore 
excluding BR1). LD Crit extends from chr5:125847699-126285172 (Figure 5.2A), completely 
encompassing Del Crit, suggesting that LMNB1 may be regulated through an element present 
within Del Crit that is excluded from all ADLD-causing duplications. Such a regulatory element 
may exhibit tissue specificity: tissues with highly proliferative cells may require consistent lamin 
B1 expression, while others with non-proliferative cells (e.g. mature oligodendrocytes) may 
require lower lamin B1 expression. Expression of LMNB1 should therefore be analyzed in multiple 
tissue types. 
5.3.3  LMNB1 expression in ADLD is highest within brain white matter 
RNA from primary fibroblasts derived from ADLD patient and control skin biopsies were 
isolated and analyzed for LMNB1 expression. Brain samples from two unrelated individuals with 
ADLD, with separate sections from grey matter (containing mostly cell bodies and few myelinated 
axons) and white matter (containing a high density of myelinated axons and oligodendrocyte cell 
bodies), were also analyzed for LMNB1 expression. mRNA analysis in fibroblasts and grey matter 
from patients with classical ADLD duplications showed moderately increased LMNB1 transcript 
with respect to control samples, consistent with previous data from patient lymphoblasts (150). 
However, duplication ADLD patients had significantly higher LMNB1 expression in white matter 
compared to controls (Figure 5.3A). ADLD patients with upstream deletions did not have 
increased LMNB1 mRNA in fibroblasts, but significantly increased LMNB1 expression in white 
matter (Figure 5.3B). Grey matter samples from deletion ADLD brains were not available. LMNB1 
expression in white matter was much higher than in fibroblasts or grey matter within all ADLD 
patients, indicating a white matter-specific mechanism of LMNB1 overexpression, independent 
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from copy number. Fibroblasts from large duplication family members show increased LMNB1 
mRNA expression over control (Figure 5.3C), with BR1 having the highest expression overall. 
However, we do not have brain samples from these patients, and therefore could not test their 
LMNB1 expression in white matter.  
 
Figure 5.3: LMNB1 expression in ADLD is higher in white matter than in grey matter or fibroblasts. 
(A) LMNB1 mRNA expression in ADLD duplication patients relative to control in fibroblasts, grey matter, and white 
matter. ADLD patients have a moderate increase of LMNB1 in fibroblasts and grey matter, but a much larger 
expression increase in white matter. K6 and A1 are families with classical ADLD. Fibroblasts were unavailable from 
A1. n = 3 for control fibroblasts and 1 for ADLD fibroblasts and brain tissues. (B) LMNB1 mRNA expression in 
deletion ADLD patients relative to control in fibroblasts and white matter. n = 3 for control fibroblasts and 1 for 
ADLD fibroblasts and white matter. (C) LMNB1 mRNA expression in large duplication fibroblasts relative to control. 
Fibroblasts from K11 family were not available. n = 3 for control fibroblasts and 1 for large duplication fibroblasts. 
5.3.4  White matter preferentially expresses duplicated LMNB1 allele in ADLD 
The 3’ untranslated region (UTR) of LMNB1 was PCR amplified and Sanger sequenced to 
search for heterozygotes of highly polymorphic SNPs, rs1051643 and rs1051644, among ADLD 
patients and controls. Heterozygotes are necessary to differentiate one copy of LMNB1 from the 
other in genomic DNA (gDNA) and mRNA. The 3’ UTR was chosen for two reasons: first, the 
SNPs in UTR regions are more common than in coding regions as they would not result in 
missense or nonsense mutations and would thus be better tolerated. Second, the SNPs must exist 
both in the gDNA as well as mRNA, so SNPs within introns would not be appropriate. For these 
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reasons, the 3’ UTR of LMNB1 was the most likely candidate to find informative SNPs. rs1051643 
and rs1051644 were chosen specifically due to their high minor allele frequencies (35% and 45%, 
respectively) so that we would have a higher chance of identifying heterozygous individuals 
(Figure 5.4A). Chromatograms from Sanger-sequenced PCR products were analyzed, and the peak 
heights of heterozygous SNPs within gDNA and mRNA from ADLD samples were compared to 
controls. cDNA reverse-transcribed from mRNA is used in PCR as a representation of mRNA 
transcript.  
A heterozygous SNP in diploid organisms would normally appear on a chromatogram as 
two superimposed peaks of different colors indicating two different alleles (Figure 5.4B). As 
expected, an equal amount of both LMNB1 alleles are amplified in the gDNA and cDNA from 
control grey matter, white matter, and fibroblasts (Figure 5.4D and 5.5A), therefore there are no 
inherent preferences of expressing one copy over another. Heterozygous SNPs in heterozygous 
duplication patients also present as double peaks, but with the duplicated allele appearing 
approximately twice as high as the non-duplicated allele (Figure 5.4C). Sequencing of ADLD grey 
matter and fibroblasts show similar peak heights in gDNA compared to cDNA (Figure 5.4E and 
3.5B). White matter samples showed a strikingly different pattern: we were only able to observe 
the SNP allele corresponding to the duplicated allele in cDNA (Figure 5.4F). This suggests that 
the duplicated copy of LMNB1 is preferentially expressed in white matter, but not in other tissues, 
indicating that the mechanism controlling LMNB1 might likely be a type of cis-regulatory element. 
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Figure 5.4: The duplicated copy of LMNB1 is preferentially expressed in ADLD white matter. 
(A) Schematic representation of LMNB1 exon 11 and the 3’ untranslated region showing the stop codon, rs1051643 
and rs1051644 SNPs, and PCR amplification primers (not to scale). (B) Representation of heterozygous SNP in a non-
duplicated locus. Grey bars represent LMNB1 locus. A representative chromatogram shows two superimposed peaks 
of equal height. (C) Representation of heterozygous SNP in a duplicated locus. Grey bars represent LMNB1 locus. A 
representative chromatogram shows the duplicated allele peak is higher than the non-duplicated allele. (D) SNP 
sequencing chromatograms in genomic DNA (gDNA, top), grey matter (GM, middle), and white matter (WM, bottom) 
of control and (E) ADLD brains K6 and CA. (F) WM of ADLD brains show a preferential expression of the duplicated 
LMNB1 allele (red arrows). 
 
Fibroblasts from an ADLD patient with a deletion upstream of LMNB1 have equal 
amplification of each LMNB1 allele in gDNA and cDNA (Figure 5.5C). In these patients, there are 
no copy number variations on LMNB1 itself, and their fibroblasts do not overexpress lamin B1 
compared to controls. Unfortunately, we do not have brain tissues from the same patient, and the 
3’ UTR
LMNB1 exon 11
TAA
rs1051643 rs1051644
For Rev
D E
F
gDNA
GM
cDNA
WM
cDNA
Control
rs1051643
ADLD – K6 ADLD – A1
ADLD – K6 ADLD – A1
gDNA
GM
cDNA
WM
cDNA
rs1051643 rs1051644
B C
T
Wild-type C C
T
Duplicated C
75 
patient from which we do have brain tissue is homozygous across all tested SNPs in the LMNB1 
coding region. Fibroblasts from large duplication patients have similar ratios of duplicated to non-
duplicated alleles in gDNA and cDNA (Figure 5.5D), except for one notable exception. Fibroblasts 
from BR1 preferentially express the duplicated LMNB1 allele, much like in ADLD white matter. 
Figure 5.5: Fibroblasts with LMNB1 duplications express the expected LMNB1 allele ratios.
(A) Heterozygous control fibroblasts show both copies at approximately equal heights in gDNA and cDNA. (B)
Fibroblasts from ADLD patients with duplicated LMNB1 show an approximately 2:1 ratio of duplicated to non-
duplicated alleles in both gDNA and cDNA. (C) Fibroblasts from an ADLD patient with a deletion upstream of
LMNB1 show equal expression of both LMNB1 alleles in gDNA and cDNA. (D) Large duplication families K9 and
Port fibroblasts have similar allele ratios in gDNA and cDNA. BR1 shows preferential overexpression of the
duplicated allele in fibroblasts (red arrow).
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5.4 Discussion 
Previous research has linked tandem LMNB1 duplications to lamin B1 overexpression and 
ADLD (77, 78, 151). All patients with LMNB1 duplications, thus far, have been shown to have 
ADLD. Here, I have shown that a duplication of LMNB1 is not the only component required for 
pathogenesis. It was assumed that more copies of the gene led to higher expression. This 
assumption is correct in certain tissues: for example, we see an increase of lamin B1 expression in 
fibroblasts from ADLD patients, correlated with the increased copy number. But LMNB1 may be 
overexpressed without being duplicated in families with a heterozygous upstream deletion, either 
from the removal of a TAD boundary that separates LMNB1 from upstream enhancer elements, or 
through a different mechanism altogether. Similarly, LMNB1 duplications themselves do not 
necessarily lead to ADLD, as families with large duplications that include a significant upstream 
region have relatively minor autonomic disorders but no ADLD. There must be an alternative 
mechanism regulating LMNB1 expression that goes beyond copy number. 
My data explain how germline duplications of LMNB1 or upstream deletions lead to CNS-
specific symptoms. The classic tandem duplications involving LMNB1 as well as upstream 
deletions that cause ADLD lead to a dramatic overexpression of lamin B1 specifically in white 
matter, more so than in other tissues, and the duplicated allele is preferentially expressed. 
Presumably, patients with large tandem duplications and without ADLD do not have greatly 
increased lamin B1 expression in their white matter, but we do not have brain samples from these 
families to test because they are unlikely to die from their mild autonomic dysfunction.  
These results together hint at a different regulatory pathway controlling LMNB1 that affects 
ADLD pathogenesis. I propose the following mechanism: an oligodendrocyte-specific cis-
regulatory element, likely a silencer, is located upstream of LMNB1 that regulates its expression. 
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It must be oligodendrocyte or at least white matter specific due to the fact that we see much higher 
LMNB1 overexpression in white matter compared to grey matter and fibroblasts from ADLD 
patients. It also much be cis-acting because the duplicated LMNB1 allele is preferentially 
overexpressed at the transcript level within white matter, overpowering the non-duplicated allele 
expression. CNVs do not directly affect LMNB1 expression to a large degree but perturb this 
silencer instead. 
I define a 145 kb critical region, “S Crit,” in which this silencer may exist: within the 
overlap of LD Crit and Del Crit but excluded from all ADLD-causing LMNB1 tandem duplications 
(chr5:125857895-126003283, Figure 5.6A). In wild-type and large duplication genomes, all copies 
of LMNB1 have an upstream silencer and are therefore not overexpressed in oligodendrocytes 
(Figure 5.6B). However, deletions of this silencer region or smaller tandem duplications resulting 
in an extra copy of LMNB1 without its silencer element lead to the overexpression of lamin B1 
specifically in white matter (Figure 5.6C). Furthermore, the insertion of BR1’s inverted duplication 
is between the transcription start of LMNB1 and the critical region of our putative silencer (81). 
Therefore, even though BR1 has a large genomic duplication including S Crit, its insertion 
separates LMNB1 from its upstream silencer, likely disrupting its suppression of transcription. The 
cause of BR1’s preferential expression of the duplicated allele and much higher lamin B1 
overexpression in fibroblasts has yet to be elucidated. This may explain BR1’s extremely severe 
ADLD symptoms and earlier onset. BR1’s case also underscores the importance of genetic testing 
methods that go beyond simple copy number determination. Assays such as aCGH, while effective 
and capable of high throughput, only give clinicians information on a patient’s genomic copy 
number and not the direction or insertion of a duplication. Determining the size, orientation, and 
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insertion of a genomic duplication through sequencing is crucial for accurate predictions of disease 
risk. 
However, the Sanger sequencing SNP analysis method used here might not be precise 
enough to draw definitive conclusions on the allelic imbalance (the extent to which one allele is 
expressed more than the other) of LMNB1 in ADLD patient white matter. Future projects should 
use more sensitive allele-specific assays such as droplet digital PCR (152) or single cell RNA-seq 
(scRNA-Seq) to more accurately determine allele frequencies expressed in mRNA. 
 
 Figure 5.6: The critical region of the oligodendrocyte-specific silencer is upstream of LMNB1. 
(A) Location of putative oligodendrocyte-specific silencer upstream of LMNB1. “Del Crit” and “LD Crit” are the 
critical regions for ADLD-causing deletions and non-ADLD large duplications, respectively. “ADLD Dup” represents 
the total span of all known ADLD-causing LMNB1 duplications. The “S Critical” region represents the area in which 
the silencer may exist, determined by including all known upstream deletions and duplications and excluding all 
known ADLD-causing duplications. (B) Mechanism of LMNB1 silencer “S” preventing LMNB1 expression and 
ADLD in wild-type and large duplication oligodendrocytes. (C) Perturbation of the silencer results in LMNB1 
overexpression in white matter, leading to ADLD. 
 
Granted, not all of lamin B1’s overexpression is due to a perturbation of this putative 
silencer. Patients with large and small duplications have increased LMNB1 transcript in fibroblasts 
and grey matter compared to normal controls, as well as a corresponding increase of duplicated 
C
A
B
Del Crit
GRAMD3 PHAX LMNB1 MARCH3
125,000,000 126,500,000
LD Crit
ADLD Dup
ALDH7A1
S Crit
chr5
Large Duplication
Wild-type
LB1
Silenced
S
LB1
Silenced
LB1
Silenced
S S
ADLD
ADLD Duplication
LB1
Silenced
LB1
Expressed
S
ADLD Deletion
LB1
Expressed
S
BR1 Duplication
LB1LB1S S
Expressed
 79 
allele expression. Copy number clearly still plays a role in the overexpression of lamin B1. 
However, copy number still does not explain the overexpression of LMNB1 in ADLD families 
with upstream deletions, and TAD boundary deletions do not explain the disease outcomes of large 
versus small genomic duplications of LMNB1. More than likely, these disparate outcomes are 
governed not by multiple regulatory pathways but by a single, common mechanism. As of yet, this 
model of an oligodendrocyte-specific cis-acting silencer offers the most complete and 
parsimonious mechanism for the genomic regulation of LMNB1 in white matter, and the 
consequences of CNVs surrounding it.  
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6.0 Overall Summary and Future Directions 
Over the course of my research, I have investigated the structure and functions of lamin B1 
and how it relates to nuclear shape maintenance and onset of ADLD. I aimed to elucidate its 1) 
structural organization within the nuclear lamina at the INM, 2) role in developing and myelinating 
oligodendrocytes, and 3) possible regulatory mechanism in white matter. I employed in vitro and 
in vivo models of lamin B1 overexpression and deletion, as well as aCGH analysis on patients 
from families with ADLD.  
Much of my research focused on the organization of lamins at the nuclear periphery. While 
investigating nuclear shape parameters by fluorescently staining cultured MEFs against lamin B1 
and lamin A/C, I noticed a peculiar pattern with some of the elongated nuclei: lamin B1 staining 
was absent in most of their polar ends, resulting in nuclei with uneven lamin B1 staining despite 
uniform lamin A/C. Initially, I thought this was a staining artifact, but this pattern consistently 
reoccurred in all subsequent experiments. What began as a questionable immunofluorescence 
staining evolved into a new paradigm for lamin organization: lamin B1 and lamin A/C form 
separate meshworks that work together to maintain nuclear structure and integrity. Previous 
research into the structural organization of the nuclear lamina have shown that A-type and B-type 
lamins tend to self-organize into independent meshworks (13, 15, 96). However, these efforts 
lacked the resolution and/or the ability to distinguish protein species to determine how A-type and 
B-type lamins are organized. We used a form of super-resolution microscopy and saw that the two 
lamin types have a concentric organization, with lamin B1 localized closer to the periphery due to 
its farnesylated C-terminus. Form follows function: the properly localized lamin B1 meshwork is 
responsible for maintaining nuclear shape. It prevents the formation of nuclear blebs arising from 
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the underlying lamin A/C meshwork. Blebs may have a function: they may be useful for rapid 
morphology changes needed to respond to forces such as sudden contraction of the cytoskeleton. 
Too much lamin B1 may prevent nuclei from immediately reacting to sudden changes in 
intracellular forces, as lamin B1 overexpression leads to increased nuclear rigidity (153). 
I then sought to expand what we know about lamin B1’s function within the cells 
responsible for myelinating the CNS: oligodendrocytes. Unlike previous research that showed 
lamin B1 knockouts in neurons leads to severe developmental disorders in mice (11), I found that 
a lamin B1 deficiency in mature oligodendrocytes does not lead to an obvious phenotype. Despite 
small changes in myelination and OPC populations early on, cKO mice did not exhibit ambulation 
deficiencies or reduced life spans. Therefore, lamin B1 might not be necessary for the survival or 
proper function of mature oligodendrocytes, consistent with previous research linking the rise of 
miR-23a and concomitant reduction of Lmnb1 expression to oligodendrocyte differentiation (145, 
154). Otherwise, there may be an as-yet unknown compensation for loss of lamin B1. 
Previously, miR-23a was found to be upregulated in MS lesions (155) and peripheral blood 
mononuclear cells (156). It would be interesting to investigate how microRNA levels change in 
ADLD versus unaffected tissues, such as whether LMNB1 overexpression leads to a concurrent 
change of microRNA expression in different tissues, and if changed microRNA levels exacerbate 
demyelination. Lamin B1 might not just be unnecessary for the proper oligodendrocyte function, 
it may in fact be detrimental. Elevated lamin B1 levels in oligodendrocytes lead to demyelination, 
consequently, mature oligodendrocytes may employ a mechanism that suppresses lamin B1 
expression.  
All in all, structure is function: onset of demyelination may be indirectly influenced by the 
organization of lamin B1 at the nuclear periphery. While lamin B1 maintains nuclear shape by 
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preventing the A-type lamin meshwork from protruding outward, it also modulates gene 
expression through interactions with chromatin. Lamina-associated domains (LADs) are regions 
of the genome that closely associate with the lamina meshwork at the INM and are associated with 
tightly condensed heterochromatin and reduced gene expression (157). In particular, lamin B1 
associates with LADs that are enriched with repressive histone marks H3K9me3 and H3K27me3 
(158), indicating transcriptional inactivation. Meanwhile, chromatin domains within nuclear blebs 
are enriched with histone marks for active transcription (13). Overexpression of lamin B1, which 
greatly reduces the formation of blebs and could conceivably increase heterochromatin binding at 
the nuclear periphery, may therefore lead to aberrant gene expression, specifically the repression 
of genes that are important for myelin production, such as those involved in lipid synthesis (80), 
and oligodendrocyte function. While lamin B1 is important for OPC differentiation, myelinating 
oligodendrocytes cannot tolerate elevated lamin B1 levels, so I propose that they employ a LMNB1 
transcriptional silencer once mature. LMNB1 overexpression and ADLD onset are due to 
perturbations of this silencer, and not necessarily from gene duplication. 
6.1 Future Directions 
6.1.1  Aim 1 future directions 
Although we have determined the organization of lamin B1 and A/C at the nuclear 
periphery, it would be interesting to investigate the organization of individual A-type lamins and 
lamin B2 as well as their interactions with other nuclear envelope proteins such as nucleoporins 
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and beta-catenin. This may have important consequences in other molecular pathways such as Wnt 
signaling in myelination and laminopathies (34, 159, 160). 
Previous research has identified lamin B1’s effect on cell proliferation and senescence (93, 
161), but not the effect of cell proliferation on lamin B1. In non-proliferating retinal neurons, lamin 
B1 is so long-lived its half-life could be measured in months (135), but during my cell culture 
experiments, I have seen lamin B1 protein levels decrease significantly after just 3 days in 
fibroblast culture (data not shown). Overexpression of lamin B1 could theoretically 
disproportionately affect post-mitotic cells such as terminally-differentiated mature 
oligodendrocytes in the CNS. This could be tested by administering cell cycle inhibitors to lamin 
B1-overexpressing fibroblasts in culture and monitor their clearance of protein. 
6.1.2  Aim 2 future directions 
Even though cKO mice did not exhibit any obvious phenotypes, future work could 
investigate their ability to remyelinate axons after white matter injury, for example induced 
through cuprizone (162) or electrolytic lesions. 
Considering the Cnp-Cre transgene does not express cre at an early enough timepoint to 
knock out lamin B1 in OPCs, Olig2-Cre;Lmnb1fl/fl conditional knockout mice would preferentially 
be used for future oligodendrocyte-specific lamin B1-knockout models. 
6.1.3  Aim 3 future directions 
CRISPR-Cas9 knockouts of the critical silencer region that was identified through aCGH 
studies would provide extremely strong evidence toward the existence of an oligodendrocyte-
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specific LMNB1 regulatory element. This could be done in vitro using immortalized 
oligodendrocyte-lineage cells (163), primary OPCs isolated via immunopanning (164), or in an in 
vivo mouse model. At 145 kb, the critical silencer region is very large, but it can be narrowed 
greatly via sequential CRISPR knockouts of increasingly narrow regions. Once sufficiently small, 
regulatory elements could be identified through bioinformatic analysis, and future experiments 
may be carried out once the nature of the putative LMNB1 suppressor is more clearly defined. For 
example, if the element is a transcription factor binding site, individual bases within that site can 
be mutated, assessing the resulting binding efficiency as well as any changes to LMNB1 
expression. In this case, we could expand ADLD genetic testing to include much smaller mutations 
such as single base pair changes that are undetectable in aCGH assays. 
RNA-seq could be used on ADLD and unaffected control brain samples to evaluate gene 
expression changes in the white matter compared to grey matter. It would also be a much more 
sensitive method to determine the allelic skew of LMNB1 in ADLD patient white matter. However, 
when using bulk RNA-seq analysis, any differences of gene expression within oligodendrocytes 
may be masked by the myriad of other cells in the brain, e.g. neurons, astrocytes, microglia, and 
endothelial cells. Single-cell RNA-seq (scRNA-seq) methods such as CITE-seq (165) would 
therefore be extremely powerful tools to correlate cell type with LMNB1 and myelin gene 
expression within the oligodendrocytes of ADLD patients. Although this may be limited by brain 
tissue availability and inconsistent harvesting methods from clinicians around the world, data from 
a very small cohort or even a single patient could provide valuable insight into lamin B1’s 
overexpression within white matter. 
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Appendix A: Tables of Antibodies 
Table A.1: Table of primary antibodies 
Primary Antibody Source Company Catalog # 
WB 
dilution 
IHC/IF 
dilution 
Lamin B1 Rabbit Abcam ab16048 1:3000 1:500 
Lamin A/C Mouse Cell Signaling 4777 1:1000 1:500 
Beta-Actin Mouse Thermo MA5-15739 1:5000  
CNP Mouse Millipore NE1020 1:1000  
GAPDH Mouse Thermo MA5-15738 1:5000  
MAG Rabbit Invitrogen 34-6200 1:1000  
MOG Mouse Santa Cruz sc-73330 1:500  
PDGFRα Rat BD Pharmingen 558774 1:100  
PLP Mouse Millipore MAB388 1:500  
Cleaved Caspase 3 Rabbit Cell Signaling 9664  1:400 
CC1 Mouse Calbiochem OP80  1:150 
MBP Rabbit Abcam ab40390  1:500 
Olig2 Rabbit Millipore AB9610  1:150 
Olig2 Mouse Millipore MABN50  1:200 
 
Table A.2: Table of secondary antibodies 
Secondary Antibody Source Company Catalog # 
WB 
dilution 
IHC/IF 
dilution 
Anti-Mouse IRDye 
680LT Goat LI-COR Biosciences 926-68020 1:10000  
Anti-Rabbit IRDye 
800CW Donkey LI-COR Biosciences 926-32213 1:10000  
Anti-Mouse Cy3 Donkey 
Jackson 
ImmunoResearch 715-165-150  1:350 
Anti-Rabbit FITC Donkey 
Jackson 
ImmunoResearch 711-095-152  1:350 
Anti-Rat Cy3 Donkey 
Jackson 
ImmunoResearch 712-165-150  1:350 
Anti-Mouse 6 nm gold Goat 
Jackson 
ImmunoResearch 115-195-068  1:10 
Anti-Rabbit 6 nm gold Goat 
Jackson 
ImmunoResearch 
111-
195-144  1:10 
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Appendix B:  Tables of Primers 
Table B.1: Genotyping primers 
Genotyping 
Primers Sequence (5' - 3') 
Product 
Size (bp) 
Cre-
Genotyping 
AGGCGTTTTCTGAGCATACCTG 
478 
AACATTCTCCCACCGTCAGTAC 
Gapdh 
GGCCTGTTTAAGGGAAAGAAGT 
324 
CCCCTTCATTGACCTCAACTAC 
Lmnb1-flox 
AACAAACTTGGCCTCACCAG 
Wt = 300 
TG = 450 CTGTGGGACAAAGACCCAGT 
CCACTTAGCTCGGGGAGTTT 
TRE-LMNB1 
AGCTCGTTTAGTGAACCGTCAG 
600 
TCAGTGCTGCTTCATATTCTCG 
Rosa26-rtTA 
GCGAAGAGTTTGTCCTCAACC  
Wt = 650 
TG = 340 AAAGTCGCTCTGAGTTGTTAT  
GGAGCGGGAGAAATGGATATG  
 
Table B.2: Miscellaneous primers 
Misc. Primers Sequence (5' - 3') Product Size (bp) 
Lmnb1-LoxP 
TGAGTTTGACACCAGCCAGAT Flox = 2100 
Wt = 1350, Del = 850 GGGGTCACATCAAATCACCTA 
Lmnb1-3'UTR 
GGAACCCCAAGAGCATCCAATA 
369 
TTATTTACCCTCCCCTCCTCAT 
 
 
  
 87 
Table B.3: Real-time PCR primers 
Real-time 
PCR Primers Sequence (5' - 3') 
M. Lmnb1 
GCTGCTCAATTATGCCAAGAAG 
GCCGCATCCTTAGAGTTTAGT 
M. Plp 
GCCCCTACCAGACATCTAGC  
AGTCAGCCGCAAAACAGACT 
M. Mbp 
CCCGTGGAGCCGTGATC  
TCTTCAAACGAAAAGGGA 
M. Mog 
ATGAAGGAGGCTACACCTGC  
CAAGTGCGATGAGAGTCAGC 
M. Mag 
AACCAGTATGGCCAGAGAGC  
GTTCCGGGTTGGATTTTACC 
M. Cnp 
GTTCTGAGACCCTCCGAAAA  
CCTTGGGTTCATCTCCAGAA 
M. Actb 
CCACTGCCGCATCCTCTTCC 
CTCGTTGCCAATAGTGATGACCTG 
H. LMNB1 
CATGAAACGCGCTTGGTAGA 
TTGCGCCAGCTTGTACTCATAC 
H. ACTB 
CACTCTTCCAGCCTTCCTTC 
GTACAGGTCTTTGCGGATGT 
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